

# Stereoselective Synthesis of N-Glycosyl Oxazolines and Evaluation of Their Antiproliferative Activity

Grigorii G. Sivets<sup>1,\*</sup>, Aleksey V. Sivets<sup>1</sup>, Maksim A. Khancheuski<sup>1</sup>

<sup>1</sup>Institute of Bioorganic Chemistry, National Academy of Sciences of Belarus, 220084 Minsk, Acad. Kuprevicha 5/2, Belarus

## Abstract

A stereoselective synthesis of protected N-glycosyl oxazolines has been developed from available acylated sugar 1,2-O-acetonides using intramolecular Ritter-like reactions. New N- $\alpha$ - and  $\beta$ -D-pentofuranosyl,  $\alpha$ -D-hexofuranosyl oxazolines as valuable intermediates for preparation of diverse N-glycosides were obtained by  $\text{BF}_3 \cdot \text{OEt}_2$ -KHF<sub>2</sub> or  $\text{BF}_3 \cdot \text{OEt}_2$ -promoted reactions of pentofuranose and hexafuranose acetonide derivatives with nitriles. When selectively acylated D-xylo- or ribofuranoses were employed in the reactions, N- $\alpha$ -pentofuranosyl oxazolines were prepared in good yields. A mechanism for the formation of glycosyl oxazolines was proposed. A series of oxazoline derivatives were evaluated for their antiproliferative activity on three human cancer cell lines (MCF-7, Hela and K562).

## Keywords

Ketal and acyl-protected carbohydrate derivatives, Ritter-like reactions, N-glycosyl oxazolines, antiproliferative activity

## Introduction

2-Oxazolines belong to an interesting class of heterocyclic compounds with versatile synthetic applications [1-2]. Carbohydrate-fused oxazolines with a C1-O-linkage have found significant use for the chemical and enzymatic synthesis of oligosaccharides [3] and glycoconjugates [4], the preparation of modified carbohydrates, and the design of synthetic oligoamidosaccharides through cationic ring-opening polymerization [5]. It is worth noting that isomeric C1-N linked N-glycosyl oxazolines are of special interest in carbohydrate chemistry and these molecules have been used as valuable intermediates in constructing different N-glycoproteins [6]. However, only a few synthetic routes have been reported to produce isomeric N-glycosyl oxazolines (Scheme 1). Garcia Fernandez and co-workers explored conversions of  $\beta$ -D-fructopyranose and D-fructofuranose 1,2-O-acetonide derivatives (**I**) with various nitriles in the presence of triflic acid to obtain spiro glycosyl oxazolines (**II**) [7] by Ritter-like transformations (Scheme 1a). Vangala and Shinde synthesized spiro 2-substituted 2-oxazolines ribosides (**II**) in good yields from 1,2;3,4-di-O-acetonide  $\beta$ -D-psicofuranose derivatives, using stereoselective TMSOTf-mediated Ritter-like reactions with nitriles [8]. One-pot syntheses of different protected N-glycooxazolines (**IV a,b**) and - glycoaminooxa-

## Research Article

## Open Access &

## Peer-Reviewed Article

## DOI:

10.14302/issn.2377-2549.jndc-23-4740

## Corresponding author:

Grigorii Sivets, Institute of Bioorganic Chemistry, National Academy of Sciences of Belarus, 220084 Minsk, Acad. Kuprevicha 5/2, Belarus.

**Received:** September 05, 2023

**Accepted:** October 04, 2023

**Published:** December 26, 2023


## Academic Editor:

Karunamoorthy Jayamoorthy,  
St. Joseph's College of Engineering.

## Citation:

Grigorii G. Sivets, Aleksey V. Sivets, Maksim A. Khancheuski (2023) Stereoselective Synthesis of N-Glycosyl Oxazolines and Evaluation of Their Antiproliferative Activity. Journal of New Developments in Chemistry - 4(2):1-23. <https://doi.org/10.14302/issn.2377-2549.jndc-23-4740>

zoline (IV c) of interest as potential inhibitors of glycosidases and chitinases have been developed by De Castra *et al.* via reactions of benzyl- and TBDMS-protected D-glucals with various amides in the presence of N-iodosuccinimide (Scheme 1b) [9]. In addition, syntheses of the protected glucopyranosyl oxazoline (IVa) were also investigated from glucopyranosyl azides (e.g., V) [6,10], 1,2-anhydroglucopyranose derivative (VI) prepared by oxidation of glucal (III) [11], but there is still need for development of practical and efficient routes to various furanosyl or pyranosyl oxazolines containing the C1-nitrogen linkage.



Scheme 1. Stereoselective synthetic routes to *N*-glycosyl oxazolines from different carbohydrate precursors


Carbohydrate-based *N*-glycosyl oxazolines have been employed as precursors in stereoselective syntheses of glycosyl isothiocyanates and amides. Acylated  $\alpha$ -glucopyranosyl isothiocyanate was synthesized from *N*-glycooxazoline using copper (II) chloride as additive, and the similar ring-opening reaction of the glycooxazoline precursor with thiophosgene afforded  $\beta$ -glucopyranosyl isothiocyanate in the absence of any additive [12]. *N*- $\alpha$ -Glycosyl amides and *N*- $\alpha$ - or  $\beta$ -glycopeptides were obtained from azide V through the formation of the intermediate glucopyranosyl oxazoline (IVa) followed by  $\alpha$ - or  $\beta$ -acylation [6,13]. The stereoselective approach to diverse *N*- $\beta$ -glycosyl amides (VII) was developed via a  $\text{PMe}_3$  mediated Staudinger reaction of glucopyranosyl azides (e.g. V) with carboxylic acid derivatives [13,14] (Scheme 1b). This paper reports a convenient and efficient method towards various *N*-furanosyl oxazolines based upon  $\text{BF}_3 \cdot \text{OEt}_2$ -promoted Ritter-like reactions of protected sugar derivatives and evaluation of the antiproliferative activity of acylated *N*-glycosyl oxazolines.

## Results and Discussion

### *Synthesis of N-glycosyl oxazolines from sugar 1,2-O-acetonides and selectively protected D-pentofuranose derivatives*

During investigation of different approaches towards fluorodeoxy D-pentofuranoses we have found that reaction of the 3-O-*p*-toluenesulfonyl xylofuranose derivative 3, prepared via diacetonide 1 [15] from D-xylose, with a 3.5-fold excess of the complex of  $\text{KHF}_2$  with dibenzo-18-crown-6 in acetonitrile in the

presence of  $\text{BF}_3 \cdot \text{Et}_2\text{O}$  resulted in the formation of N-xylofuranosyl oxazoline **7** after the basic aqueous work-up of the reaction mixture and chromatography on silica gel. A selective transformation of the xylofuranose acetonide derivative **3** with the solvent was observed at the 1,2-O-isopropylidene group in the presence of the Lewis acid (6-7.0 equiv) without formation of fluorinated products by a nucleophilic substitution reaction of the 3-O-*p*-toluenesulfonyloxy group with inorganic fluoride (Scheme 2). However, application of crown ether gave rise to tedious purification of the product by column chromatography. No reaction was observed under treatment of the tosylate **3** with a 3.5-fold excess of  $\text{KHF}_2$  in  $\text{CH}_3\text{CN}$  at rt and only the starting acetonide was recovered unchanged. Further, it was shown that the oxazoline **7** can be prepared from the acetonide derivative **3** in a high 98% yield using  $\text{BF}_3 \cdot \text{Et}_2\text{O}$ / $\text{KHF}_2$  in  $\text{CH}_3\text{CN}$  without column chromatography on silica gel (Scheme 2) as compared to the previous findings reported earlier [16].

























Scheme 2. Synthetic study of N-glycosyl oxazolines from sugar acetonides











In the course of present comprehensive study, conversions of various protected D-pentofuranose and -hexofuranose acetonides with nitriles to glycosyl oxazoline derivatives were explored under  $\text{BF}_3 \cdot \text{Et}_2\text{O}$ / $\text{KHF}_2$  reaction conditions at room temperature (Scheme 2 and Table 1). The reaction of the 3-O-mesyl xylofuranose derivative **4** gave the oxazoline **8** in 93% yield without formation of nucleophilic substitution products as with the tosylate **3**. N-Pentofuranosyl oxazolines **9**, **13** and **16** were synthesized in high 96-99% yields in acetonitrile (Table 1, entries 3, 7 and 9) from isomeric benzoylated 1,2-O-isopropylidene-D-pentofuranose derivatives **5-6**, and **15**, prepared by the known methods described earlier from D-xylose and arabinose [17-21]. 1,2;3,5-Di-O-isopropylidene-D-xylofuranose (**1**) also afforded the protected xylofuranosyl oxazoline **12** in 76% yield as the result of regioselective transformations in the 1,2-O-isopropylidene group (table 1, entry 6). The reactions of benzoyl-protected D-xylofuranose, ribofuranose and arabinofuranose 1,2-O-acetonides studied in acetonitrile at room temperature gave rise to the stereoselective formation of *cis*-fused bicyclic N- $\alpha$ - and  $\beta$ -D-pentofuranosyl

oxazolines after the work-up of the reaction mixture without using column chromatography on silica gel (Table 1, entries 1-3, 6,7 and 9). Further, we explored scope of the  $\text{BF}_3 \cdot \text{Et}_2\text{O}$ - $\text{KHF}_2$ -mediated reaction of benzoylated 1,2-O-isopropylidene-D-pentofuranose derivatives with other nitriles such as propionitrile and benzonitrile. The reaction **6** with benzonitrile or propionitrile gave oxazolines **10** and **11** in 97% and 86% yields, respectively (entries 4 and 5). The protected  $\alpha$ -ribofuranosyl and  $\beta$ -arabinofuranosyl oxazolines **14** and **17** were smoothly prepared from the Ritter-like reactions of acylated 1,2-O-acetonides of **6** and **15** in benzonitrile in 97% yield (Table 1, entries 8 and 10). Next, the above stereoselective reactions were investigated for acyl-protected hexofuranose 1,2-O-acetonide derivatives under the similar conditions. 3,5,6-Tri-O-benzoyl-1,2-O-isopropylidene- $\alpha$ -D-glucofuranose (**18**) as well as isomeric allofuranose derivative **24**, prepared according to the known methods [22], gave protected N-glycofuranosyl oxazolines **19** and **20** in acetonitrile and benzonitrile, oxazoline **25** in benzonitrile, respectively, in the high yields (Table 1, entries 11, 12 and 15). The Ritter reaction of fully O-acetylated 1,2-O-acetonide- $\alpha$ -D-glucofuranose **21** [23] or  $\alpha$ -D-allofuranose **26** [24] in acetonitrile or benzonitrile furnished oxazolines **22** (entry 13), **23** (entry 14) and **27** (entry 16) in 95-98% yields. The structures of synthesized oxazolines were supported by  $^1\text{H}$ ,  $^{13}\text{C}$  NMR, IR spectral data and mass spectra (Experimental part). Resonance signals of  $\text{CH}_3$  groups of oxazoline rings for all synthesized glycosyl oxazolines were observed as singlets in the range of  $\sim 1.97$ - $2.18$  ppm and  $13.2$ - $14.2$  ppm [7] in  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra,

Table 1. Synthesis of *N*-pentofuranosyl and *N*-hexofuranosyl oxazolines from protected D-sugar acetonides using  $\text{BF}_3 \cdot \text{OEt}_2$ - $\text{KHF}_2$ -promoted reactions with nitriles

| Entry | Protected acetonide                                                                 | Nitrile                         | Time (h) | $\text{KHF}_2/\text{BF}_3 \cdot \text{Et}_2\text{O}$ (Mol equiv) | Product                                                                               | Yield <sup>a</sup> (%) |
|-------|-------------------------------------------------------------------------------------|---------------------------------|----------|------------------------------------------------------------------|---------------------------------------------------------------------------------------|------------------------|
| 1     |  | $\text{CH}_3\text{CN}$          | 18       | 3.0/7.2                                                          |  | 98%                    |
| 2     |  | $\text{CH}_3\text{CN}$          | 18       | 3.1/7.2                                                          |  | 93%                    |
| 3     |  | $\text{CH}_3\text{CN}$          | 18       | 3.5/6.3                                                          |  | 96%                    |
| 4     |  | $\text{C}_6\text{H}_5\text{CN}$ | 18       | 3.5/6.2                                                          |  | 97% <sup>b</sup>       |

|    |                                                                                           |                                  |    |         |                                                                                             |                  |
|----|-------------------------------------------------------------------------------------------|----------------------------------|----|---------|---------------------------------------------------------------------------------------------|------------------|
| 5  | <br>5    | C <sub>2</sub> H <sub>5</sub> CN | 18 | 2.7/4.9 | <br>11   | 86% <sup>c</sup> |
| 6  | <br>1    | CH <sub>3</sub> CN               | 4  | 2.1/6.2 | <br>12   | 76%              |
| 7  | <br>6    | CH <sub>3</sub> CN               | 18 | 3.5/6.3 | <br>13   | 99%              |
| 8  | <br>6   | C <sub>6</sub> H <sub>5</sub> CN | 18 | 2.7/6.2 | <br>14  | 97% <sup>b</sup> |
| 9  | <br>15 | CH <sub>3</sub> CN               | 18 | 3.5/6.3 | <br>16 | 99%              |
| 10 | <br>15 | C <sub>6</sub> H <sub>5</sub> CN | 18 | 4.8/6.3 | <br>17 | 97% <sup>b</sup> |
| 11 | <br>18 | CH <sub>3</sub> CN               | 18 | 3.4/8.4 | <br>19 | 93%              |

|    |                                                                                     |            |    |         |                                                                                       |                  |
|----|-------------------------------------------------------------------------------------|------------|----|---------|---------------------------------------------------------------------------------------|------------------|
| 12 |    | $C_6H_5CN$ | 18 | 4.9/8.3 |    | 92% <sup>b</sup> |
| 13 |    | $CH_3CN$   | 18 | 2.5/8.1 |    | 95%              |
| 14 |    | $C_6H_5CN$ | 18 | 4.9/8.3 |    | 92% <sup>b</sup> |
| 15 |   | $C_6H_5CN$ | 18 | 4.3/8.3 |   | 86% <sup>b</sup> |
| 16 |  | $CH_3CN$   | 18 | 2.4/8.0 |  | 98%              |

<sup>a</sup> Isolated yield after basic treatment of reaction mixture without CC on silica gel

<sup>b</sup> Isolated yield after column chromatography on silica gel


<sup>c</sup> Yield was determined from  $^1H$  NMR spectral data of the reaction mixture

respectively, measured in  $CDCl_3$ . Signals of the tertiary carbon atoms of the sugar oxazolines with 2-Me, Et or Ph substituents displayed at 167-173 ppm in  $^{13}C$  NMR spectra. Absorption bands of the  $-C=N$ -bonds were revealed at 1642-1675  $cm^{-1}$  in IR-spectra of *N*-glycosyl oxazolines.

Thus, we have found that the Ritter-like reactions [25-26] of the protected pentofuranose and hexofuranose 1,2-O-acetonides with nitriles in the presence of  $BF_3 \cdot Et_2O$  and  $KHF_2$  resulted in stereoselective transformations in the 1,3-dioxolane ring to give the only reaction products containing the five-membered 2-oxazoline derivatives. Next, to understand the assumed role of  $KHF_2$  as a promoter with acidic properties in the studied conversions of acetonides **1**, **3** and **5** into glycosyl  $\alpha$ -D-oxazolines in the presence of  $BF_3 \cdot Et_2O$ , the Ritter-like reaction of benzoylated D-xylofuranose 1,2-O-acetonide **5** was tested with acetonitrile in the presence of 7.2 equiv of  $BF_3 \cdot Et_2O$  and 3.4 equiv of *p*-toluenesulfonic acid instead of  $KHF_2$  at room temperature (Scheme 3, conditions a).



The oxazoline **9** was prepared in 78% yield after column chromatography on silica gel. Besides, the  $\text{BF}_3 \cdot \text{Et}_2\text{O}$ - $\text{KHF}_2$ -assisted reaction of the tosylate **3** in acetonitrile was studied in the presence of  $\text{NaBH}_4$  at room temperature (Scheme 3, conditions b). Such treatment of compound **3** did not result in the reduction of the C3-O-*p*-toluenesulfonyloxy group and acyclic product **30** was obtained in 40% yield after chromatography on silica gel. The structure of the xylitol derivative **30** was confirmed by the preparation of fully O-benzoylated derivative **31** (70%) and analysis of their  $^1\text{H}$  and  $^{13}\text{C}$  NMR, HRMS spectral data. Proposed synthetic pathway to compound **30** via the possible reductive cleavage of the ketal-protected xylofuranose derivative **3** is outlined in Scheme 3. Activation of the 1,3-dioxolane ring in **3** may proceed in the presence of the Lewis acid  $\text{BF}_3$  or an acidic promoter with generation of intermediate **29** in the first step. Then, the formation of an intermediate oxocarbenium ion **29** occurs from **28**. A selective reduction of aldofuranose counterpart of **29** with diborane forming in situ from  $\text{NaBH}_4$  and  $\text{BF}_3$  yields the selectively protected xylitol derivative **30** in the next steps (Scheme 3). The



Scheme 3. Study of  $\text{BF}_3 \cdot \text{OEt}_2$ -assisted transformations of protected xylofuranose acetonides **3** and **5** on the 1,3-dioxolane ring in acetonitrile. Reagents and conditions: (a) **5**,  $\text{CH}_3\text{CN}$ , *p*- $\text{TsOH}$ ,  $\text{BF}_3 \cdot \text{Et}_2\text{O}$ , rt, 18 h; 1N aq  $\text{NaOH}$ , **9**, 78%; (b) **3**,  $\text{KHF}_2/\text{BF}_3 \cdot \text{Et}_2\text{O}$ ,  $\text{NaBH}_4$ ,  $\text{CH}_3\text{CN}$ , rt, 5% aq  $\text{NaHCO}_3$ , 40%, **30**; (c)  $\text{BzCl}$ , Py, rt, **31**, 65%.

above findings indicate that the  $\text{BF}_3 \cdot \text{Et}_2\text{O}$ -mediated reactions of benzoylated D-pentofuranose 1,2-acetonides imply a regioselective activation of the 1,2-O-isopropylidene group with involvement of the Lewis acid and acid promoters such as  $\text{KF} \cdot \text{HF}$  or *p*- $\text{TsOH}$ , as with the Ritter-like reactions described for the fructofuranose acetonides in the presence of triflic acid [7] or natural monosaccharides in liquid HF [27].

To further explore Ritter reactions, syntheses of the protected N-glycosyl oxazolines were investigated from the D-pentofuranose **1**, **3**, **5** and hexofuranose **18**, **21**, **24** acetonide derivatives under various Lewis acid-assisted conditions (Table 2).

The control Ritter reaction of xylofuranose acetonides **3** or **5** was tested in acetonitrile in the presence of catalytic amounts of  $\text{BF}_3 \cdot \text{Et}_2\text{O}$  (0.5-0.8 equiv) and the excess of  $\text{KHF}_2$  (3.5 equiv). No formation of oxazolines **7** and **9** was observed under these conditions (Table 2, entries 1 and 2). The reactions of acetonides **3** and **5** did not proceed in MeCN containing the excess of  $\text{KHF}_2$  or a complex of  $\text{KHF}_2$  with 18 crown 6 prepared previously in anhydrous methanol (entries 3 and 4). It was found that treatment of acetonides **3** and **5**, unlike diacetonide **1** (entry 9), with 7.2 and 6.3 equiv of  $\text{BF}_3 \cdot \text{Et}_2\text{O}$  in dry acetonitrile without  $\text{KHF}_2$  led to oxazolines **7** and **9** in high 93% and 92% yields, respectively (entries 7 and 8). Ritter

Table 2. Screening in Ritter-like reactions of protected xylofuranosyl, glucofuranosyl and allofuranosyl acetonides with nitriles under the Lewis acid activated conditions

| Entry | Protected acetonide | Reaction conditions                                                                                      | Oxazoline (yield,%) <sup>a</sup> |
|-------|---------------------|----------------------------------------------------------------------------------------------------------|----------------------------------|
| 1     | <b>3</b>            | BF <sub>3</sub> ·Et <sub>2</sub> O (0.5 equiv)/CH <sub>3</sub> CN/KHF <sub>2</sub> (3.5 equiv), rt, 18 h | -                                |
| 2     | <b>5</b>            | BF <sub>3</sub> ·Et <sub>2</sub> O (0.8 equiv)/CH <sub>3</sub> CN/KHF <sub>2</sub> (3.5 equiv), rt, 18 h | -                                |
| 3     | <b>3</b>            | CH <sub>3</sub> CN/ KHF <sub>2</sub> (5.6 equiv)·18 crown 6, rt, 18 h                                    | -                                |
| 4     | <b>5</b>            | CH <sub>3</sub> CN/KHF <sub>2</sub> (3.5 equiv), rt, 18 h                                                | -                                |
| 5     | <b>5</b>            | BF <sub>3</sub> ·Et <sub>2</sub> O (2.0 equiv)/CH <sub>3</sub> CN/KHF <sub>2</sub> (3.5 equiv), rt, 18 h | <b>9</b> (20%)                   |
| 6     | <b>5</b>            | BF <sub>3</sub> ·Et <sub>2</sub> O (3.0 equiv)/CH <sub>3</sub> CN/KHF <sub>2</sub> (3.5 equiv), rt, 18 h | <b>9</b> (87%)                   |
| 7     | <b>3</b>            | BF <sub>3</sub> ·Et <sub>2</sub> O (7.2 equiv)/CH <sub>3</sub> CN, rt, 18 h                              | <b>7</b> (93%)                   |
| 8     | <b>5</b>            | BF <sub>3</sub> ·Et <sub>2</sub> O (6.3 equiv)/CH <sub>3</sub> CN, rt, 18 h                              | <b>9</b> (92%)                   |
| 9     | <b>1</b>            | BF <sub>3</sub> ·Et <sub>2</sub> O (6.2 equiv)/CH <sub>3</sub> CN, rt, 3 h                               | <b>12</b> (54%) <sup>b</sup>     |
| 10    | <b>5</b>            | BF <sub>3</sub> ·Et <sub>2</sub> O (6.3 equiv)/PhCN, rt, 18 h                                            | <b>10</b> (91%) <sup>b</sup>     |
| 11    | <b>5</b>            | BF <sub>3</sub> ·Et <sub>2</sub> O (4.9 equiv)/EtCN, 0 <sup>0</sup> → rt, 18 h                           | <b>11</b> (72%)                  |
| 12    | <b>18</b>           | BF <sub>3</sub> ·Et <sub>2</sub> O (7.5 equiv)/PhCN, rt, 18 h                                            | <b>20</b> (44%) <sup>b</sup>     |
| 13    | <b>21</b>           | BF <sub>3</sub> ·Et <sub>2</sub> O (7.6 equiv)/PhCN, rt, 18 h                                            | <b>23</b> (40%) <sup>b</sup>     |
| 14    | <b>24</b>           | BF <sub>3</sub> ·Et <sub>2</sub> O (7.8 equiv)/PhCN, rt, 18 h                                            | <b>25</b> (50%) <sup>b</sup>     |
| 15    | <b>3</b>            | TMSOTf (7.2 equiv)/CH <sub>3</sub> CN/KHF <sub>2</sub> (3.5 equiv), rt, 18 h                             | <b>7</b> (98%)                   |
| 16    | <b>3</b>            | TMSOTf (7.2 equiv)/CH <sub>3</sub> CN, rt, 18 h                                                          | <b>7</b> (95%)                   |


<sup>a</sup> Yield was determined from <sup>1</sup>H NMR spectral data of the reaction mixture<sup>b</sup> Isolated yield after column chromatography on silica gel

reactions of benzoylated xylofuranosyl acetonide **5** with benzonitrile or propionitrile in the presence of 6.0 or 4.9 of equiv BF<sub>3</sub>·Et<sub>2</sub>O resulted in oxazolines **10** and **11** in 91% and 72% yields (entries 8 and 9). The Ritter reaction of *O*-benzoylated or acetylated 1,2-*O*-acetonide-*D*-glucofuranose derivatives **18** and **21** with benzonitrile in the presence of BF<sub>3</sub>·Et<sub>2</sub>O (7.5 equiv) gave the oxazolines **20** and **23** in 44% and 40% yields (entries 12 and 13) compared to the same reactions under the BF<sub>3</sub>·Et<sub>2</sub>O-KHF<sub>2</sub>-promoted conditions (92% and 95%) (Table 1, entries 12 and 13). The allofuranosyl oxazoline derivative **25** was prepared in high yields using the BF<sub>3</sub>·Et<sub>2</sub>O-KHF<sub>2</sub>- or BF<sub>3</sub>·Et<sub>2</sub>O conditions for Ritter reactions of the *D*-allofuranose acetonide **24** with benzonitrile in the presence of 7.5 equiv of the Lewis acid (Table 2, entry 14 and Table 1, entry 15). Ritter reactions of the acetonide **3** with acetonitrile have been tested using the TMSOTf-KHF<sub>2</sub> or TMSOTf-mediated conditions (entries 15 and 16) and the oxazoline **7** was prepared in 98% and 95% yields, respectively.

After screening of various BF<sub>3</sub>·Et<sub>2</sub>O-promoted reactions of xylofuranose acetonides **1**, **3**, and **5** with different protecting groups we have found that benzoyl-protected N-glycosyl oxazolines can be prepared in good yields under the BF<sub>3</sub>·Et<sub>2</sub>O-KHF<sub>2</sub> (Tables 1) or BF<sub>3</sub>·Et<sub>2</sub>O (table 2) conditions in the presence of the excess of the Lewis acid. In the case of a series of acylated hexofuranose 1,2-*O*-acetonide derivatives **18**, **21**, **24** and **26**, the excess of the Lewis acid (about 8 equiv) along with KHF<sub>2</sub> (2.5-4.0 equiv), that may generate HF or HBF<sub>4</sub> and KBF<sub>4</sub> after interaction with the strong Lewis acid in polar solvent, needs for conversions of acetonides into oxazolines under the BF<sub>3</sub>·Et<sub>2</sub>O-KHF<sub>2</sub> (Table 1, entries 11-16) with good yields compared to the BF<sub>3</sub>·Et<sub>2</sub>O-promoted reactions for glucofuranose acetonides **18**, **21** and



allofuranose acetonide **24** (table 2, entries 12-14). It is important to note that selection of optimal conditions (the use of the acidic promoter, ratio of reagents, excess of LW) for achieving high yields of glycosyl oxazolines in the Ritter reactions under consideration depends on the structure of the starting sugar, a character of protecting groups and nitrile used as solvent/reagent. Based on analysis of different conditions explored for a series of the Ritter-like reactions of sugar acetonides, mechanistic pathways leading to the formation of N- $\alpha$ -glycosyl oxazolines from protected xylofuranose acetonides **1**, **3** and **5** were proposed (Schemes 4 and 5). Proposed mechanism for stereoselective  $\text{BF}_3\cdot\text{Et}_2\text{O}$ - $\text{KHF}_2$ -assisted reactions of xylofuranose acetonide derivatives **3** and **5** with nitriles is illustrated in Scheme 4.



Scheme 4. Proposed mechanism for the formation of oxazolines from D-xylofuranose acetonide derivatives **3** and **5**

The synthetic route to protected N- $\alpha$ -xylofuranosyl oxazolines likely to include the formation of intermediate ions **32a** and **32b** with assistance of a mild acidic promoter (gradual generation from  $\text{KHF}_2$  in the presence of excess of  $\text{BF}_3\cdot\text{Et}_2\text{O}$  in polar solvent) and the Lewis acid, and the subsequent occurrence of oxocarbenium ions **33** and **34**, respectively [12, 27]. We suggest that mechanistic pathway towards the nitrilium intermediate **35** from tosylate **3** may occur through a direct nitrile addition to the furanosyl oxocarbenium ion **33** from  $\alpha$  or  $\beta$ -face and without remote participation of the protecting groups. The formation of the thermodynamically more stable the  $\alpha$ -nitrilium ion **35** as compared with an intermediate  $\beta$ -nitrilium ion is probably favored by activated with the Lewis acid the 2-hydroxyl group, which is capable of stabilizing the adjacent cation via interaction with the  $\alpha$ -nitrilium group in the presence of  $\text{BF}_3$ . Notice that the preferential generation of an intermediate stable  $\alpha$ -nitrilium ion under the conversion of the protected xylofuranose derivative in  $\text{CD}_3\text{CN}$  in the presence of the Lewis acid ( $\text{Me}_3\text{OBF}_4$ ) has been supported by Turnbull and co-workers using  $^1\text{H}$  NMR experimental data and DFT


calculations [28]. The kinetically controlled formation of the  $\alpha$ -xylofuranosyl nitrilium ion **35** can result from the oxocarbenium ion **33** or contact tetrafluoroborate ion pairs via solvation of the intermediate oxonium cation under  $S_N1$ -reaction and a fast attack with nitrile from the  $\alpha$ -face due to an anomeric effect, as has been reported for the glycosylation reactions of pyranose derivatives through pyranosyl nitrilium ions [29-32]. The generation of oxazolinium intermediate **37** [29] proceeds from the cation **36** via intramolecular trapping of the 2-O-hydroxyl group with the electrophilic nitrilium carbon.

Another possible pathway for formation of acylated *N*- $\alpha$ -xylofuranosyl oxazolines via generation of intermediate cyclic benzoxonium ions with participation of acyl protecting groups should be considered in the case of  $\text{BF}_3 \cdot \text{Et}_2\text{O} \cdot \text{KHF}_2$ -assisted reactions of benzoylated D-xylofuranose 1,2-O-acetonide **5**.  $\alpha$ -Xylofuranosyl nitrilium intermediates may arise by nitrile addition to the intermediate cyclic 1,3(1,5)-dioxacarbenium ions, which would be produced via assistance of the O-benzoyl groups in the oxocarbenium ion **34** in the presence of the Lewis acid. The influence of vicinal and remote O-acyl groups has been invoked on many glycosylation reactions of monosaccharide derivatives in the presence of Lewis acids [32-34]. The remote stereodirecting participation of 3-O- or 4-O-acyl (benzoyl, 4-methylbenzoyl or acetyl) protecting groups and their distinct stereochemical effects for promoted glycosylation reactions of protected pyranoses and furanoses as glycosyl donors have earlier been examined [34,35]. An interesting concept of catalysis for the glycosylation reactions was reported which was introduced by the Schmidt group [36-38]. It includes activation of acceptor and glycosyl donor in the presence of Lewis acids as catalysts followed by generation of a cyclic intermediate to give rise to O-glycoside(s) as a result of the stereoselective glycosidation. From those mechanistic considerations, pathway for the  $\text{BF}_3 \cdot \text{Et}_2\text{O} \cdot \text{KHF}_2$ -promoted reaction of acetonide **5** was proposed (Scheme 4). One may pass through an intermediate transition state or complex **38** that originates from coordination of a transient glycosyl cation, stabilized by the remote participation of 3-O-benzoyl group in the oxocarbenium ion, with acetonitrile under assistance of the 2-OH group activated in the presence of  $\text{BF}_3 \cdot \text{Et}_2\text{O}$  as a strong Lewis acid [32, 37].

The further stereoselective course of the Ritter reaction of acetonide **5** would result in  $\alpha$ -xylofuranosyl nitrilium ions **39** and generation of an adduct **40** as a complex of the oxazoline with  $\text{BF}_3$ . The basic work-up of intermediate oxazolinium derivatives **37** and **40** with aqueous sodium hydroxide gave protected *N*- $\alpha$ -xylofuranosyl oxazolines **7**, **9-11** (Scheme 4).


Two different pathways for  $\text{BF}_3 \cdot \text{Et}_2\text{O}$ -promoted Ritter-like reactions of D-xylofuranose diacetonide **1**, bearing non-participating isopropylidene groups, are shown in Scheme 5.

The formation of the oxazoline **12** from diacetonide **1** in acetonitrile under the  $\text{BF}_3 \cdot \text{Et}_2\text{O} \cdot \text{KHF}_2$ -assisted conditions (a) may proceed via the oxocarbenium ion **41** after a regioselective activation of the 1,2-O-isopropylidene group with an acidic promoter and the Lewis acid followed by generation of the oxazolinium intermediate **42** similar to conversions of the 3-O-tosyl xylofuranose derivative **3** (Scheme 4) into the oxazoline **7** through the cation **36** and key oxazolinium derivative **37**. Under the  $\text{BF}_3 \cdot \text{Et}_2\text{O}$ -mediated conditions (b), the Ritter-like reaction of **1** with acetonitrile would occur in a different pathway through activation of the 1,3-dioxolane ring with  $\text{BF}_3 \cdot \text{Et}_2\text{O}$  in the first step, generation of the oxocarbenium ion **43** and a subsequent bottom attack of solvent to give the  $\beta$ -nitrilium intermediate **44**, as has been reported for the preparation of oxazolines by reacting epoxides with nitriles in the presence of Lewis acids [11, 39]. The further inversion of **44** at C1 with acetonitrile would result in an intermediate  $\alpha$ -nitrilium ion, and subsequently the electrophilic  $\alpha$ -nitrilium cation **45**, a complex of the oxazoline with the Lewis acid **46**, giving the target oxazoline **16** after the basic work-up.



Scheme 5. Proposed intermediates during  $\text{BF}_3\cdot\text{Et}_2\text{O}$ -promoted reactions of diacetone **1** with acetonitrile

In order to explore the scope of the  $\text{BF}_3\cdot\text{Et}_2\text{O}$ -mediated approach for other protected D-pentofuranose derivatives with free hydroxyl groups we have undertaken synthesis of N-xylofuranosyl oxazolines from selectively benzoylated xylofuranoses **47-48** readily prepared by the acidic removal of 1,2-O-isopropylidene groups from xylofuranose acetonide derivatives **2** and **5** with aqueous trifluoroacetic acid (Scheme 6, conditions  $a_{1-2}$ ). 5-O-Benzoyl- $\alpha,\beta$ -D-xylofuranose (**47**) gave the benzoyl-protected oxazoline **49** (75%) under the the  $\text{KHF}_2\text{-BF}_3\cdot\text{Et}_2\text{O}$  conditions (conditions  $b_1$ ). Interestingly, the reaction of 3,5-di-O-



Scheme 6. Synthesis of acylated D-xylo-, ribo- and arabinofuranosyl oxazolines. Reagents and conditions: ( $a_1$ ) **2**, 93% aq TFA, rt, 2 h, **47**, 80%; ( $a_2$ ) **5**, 93% aq TFA, rt, 2 h, **48**, 80%; ( $b_1$ ) benzoylated D-xylofuranoses **47-48**,  $\text{CH}_3\text{CN}$ ,  $\text{KHF}_2\cdot\text{BF}_3\cdot\text{Et}_2\text{O}$ , rt, 3-4 h, 5 % aq  $\text{NaHCO}_3$ , **49**, 75%; **9**, 99%; ( $c_1$ ) **48**,  $\text{CH}_3\text{CN}/\text{BF}_3\cdot\text{Et}_2\text{O}$ , rt, 3 h, 5 % aq  $\text{NaHCO}_3$ , **9**, 65%; ( $b_2$ ) **50**,  $\text{CH}_3\text{CN}$ ,  $\text{KHF}_2\cdot\text{BF}_3\cdot\text{Et}_2\text{O}$ , rt, 3 h, 1N aq  $\text{NaOH}$ , **13**, 99%; ( $c_2$ ) **50**,  $\text{CH}_3\text{CN}$ ,  $\text{BF}_3\cdot\text{Et}_2\text{O}$ , rt, 3 h, 1N aq  $\text{NaOH}$ , **13**, 65%; d) **17**,  $\text{NH}_3/\text{MeOH}$ , rt, 18 h, **51**, 93%; e) **51**,  $\text{Ac}_2\text{O}$ , Py, rt, **52**, 80%.

benzoyl- $\alpha,\beta$ -D-xylofuranose (**48**) in acetonitrile furnished the oxazoline **9** (99%), as in the case of the Ritter reaction of 3,5-di-O-benzoyl-1,2-O-isopropylidene- $\alpha$ -D-xylofuranose (**5**) (Table 1, entry 3).

In addition, the Ritter-like reaction of **48** with acetonitrile in the presence of  $\text{BF}_3 \cdot \text{Et}_2\text{O}$  (6.0 equiv) without  $\text{KHF}_2$  (conditions  $c_1$ ) also afforded the protected N- $\alpha$ -xylofuranosyl oxazoline **9** (65%). Furthermore, we have found that the Lewis acid promoted reactions of 1,3,5-tri-O-benzoyl- $\alpha$ -D-ribofuranose (**50**) [40] with  $\text{CH}_3\text{CN}$  in the presence of  $\text{KHF}_2$  or without the inorganic salt gave the  $\alpha$ -oxazoline **13** in 99% and 65% yields, respectively, after the basic work-up of reaction mixtures (Scheme 6, conditions  $b_2$  and  $c_2$ ). Removing benzoyl protecting groups in the oxazoline **17** with  $\text{NH}_3/\text{MeOH}$  (conditions d) resulted in the  $\beta$ -arabinofuranosyl oxazoline **51** (93%). Acetylation of the latter with acetic anhydride in pyridine at room temperature afforded fully O-acetylated oxazoline **52** in 80% yield.

From the above-considered synthetic routes to oxazolines from protected D-pentofuranose derivatives it should be noted that the  $\text{BF}_3 \cdot \text{Et}_2\text{O}$ -promoted reactions of selectively acylated D-xylofuranose and -ribofuranose derivatives (Scheme 6), diacetonide **1** (Scheme 5) and acylated 1,2-O-isopropylidene- $\alpha$ -D-pentofuranoses **3**, **5**, **6** and **15** (Schemes 4 and 3) differ in producing intermediate oxocarbenium ions in the presence of the Lewis acid in the first steps and, probably, different oxazolinium intermediates in the next steps. The formation of  $\alpha$ -nitrilium ions is the general peculiarity for the Ritter-like transformations of D-xylofuranose and -ribofuranose derivatives studied with nitriles. Prepared sugar oxazolines can be used for obtaining various N-glycosyl amides via hydrolysis reactions and novel N-glycoside derivatives.

#### *In vitro* antiproliferative activity of N-glycosyl oxazoline derivatives with 2-phenyl substituent

A series of newly synthesized N-glycosyl oxazoline derivatives with 2-phenyl substituent were tested for their *in vitro* inhibitory effects on proliferation of myelogenous leukemia (K562), cervical carcinoma (Hela) and breast carcinoma (MCF-7) using the resazurin assay [41] ] that, together with other high-throughput screening methods, had been developed previously to measure viability or cytotoxicity [42]. 5-Fluorouracil (5-FU) was used as the reference compound. The findings are listed in Table 3.

Table 3. Antiproliferative activities of a series of N-glycosyl oxazoline derivatives with 2-phenyl substituent on human cancer cell lines

| Compound    | $\text{IC}_{50}^a$ (mM) |                  |                  |
|-------------|-------------------------|------------------|------------------|
|             | MCF-7                   | K-562            | Hela             |
| <b>10</b>   | 99.76 $\pm$ 0.45        | > 100            | > 100            |
| <b>14</b>   | > 100                   | 23.01 $\pm$ 0.31 | 63.92 $\pm$ 0.21 |
| <b>17</b>   | 79.4 $\pm$ 0.34         | > 100            | > 100            |
| <b>20</b>   | > 100                   | > 100            | 21.92 $\pm$ 0.25 |
| <b>51</b>   | NI                      | NI               | NI               |
| <b>52</b>   | > 100                   | > 100            | > 100            |
| <b>5-FU</b> | 26.32 $\pm$ 0.32        | 11.02 $\pm$ 0.26 | 32.43 $\pm$ 0.17 |

<sup>a</sup>  $\text{IC}_{50}$  is concentration of compound required to inhibit cancer cell proliferation by 50%.  $\text{IC}_{50}$  values were calculated from the cell growth inhibition curves obtained from the treatments done with increasing concentrations. NI: no inhibition.

Among N-pentofuranosyl oxazolines with *xylo*-, *ribo*- and *arabino*-configurations tested (compounds **10**, **14**, **17**, **51** and **52**), only benzoylated *xylo*- and *arabino*furanosyl oxazolines **10** and **17** displayed weak inhibitory effects against MCF cell line with IC<sub>50</sub> values of 99.76 and 79.4  $\mu$ M, respectively. Unlike to isomeric *xylo*- and *arabino*-furanosyl oxazolines **10** and **17**, 3,5-di-*O*-benzoyl  $\alpha$ -ribofuranosyl oxazoline **14** showed moderate activity with IC<sub>50</sub> value of 63.92  $\mu$ M in Hela cells and good antiproliferative activity against K562 cell line (IC<sub>50</sub> 23.01  $\mu$ M). Deprotected N- $\beta$ -D-arabinofuranosyl oxazoline **51** did not show activity on all cell lines at the highest concentration of tested compound. The benzoylated N- $\alpha$ -glycofuranosyl oxazoline derivative **20**, bearing 2-phenyl substituent in the oxazoline ring, displayed significant antiproliferative activity with IC<sub>50</sub> value (21.92  $\mu$ M) comparable to those of the known nucleobase analog 5-FU on Hela cells. Comparative biological assessment of the oxazoline **20** and its close structural analogs the N-glycosyl oxazoline derivatives **23** and **25** is underway in cancer cell lines. To gain insight into the mode action/mechanism for the inhibitory effects of the oxazolines with 2-phenyl substituent, the apoptosis assays for compound **20** as well as its two analogs are currently under investigation in Hela cancer cell line, applying DAPI and Annexin V-FITC/PI staining methods, and the results will be published elsewhere.

### Conclusion

In summary, a convenient and stereoselective approach to prepare various N-glycosyl oxazolines has been developed from sugar 1,2-*O*-acetonides using mild reaction conditions for the BF<sub>3</sub>·OEt<sub>2</sub>-mediated Ritter-like reactions. Scope of a novel method based upon the reactions of selectively protected D-pentofuranose derivatives with nitriles as solvents in the presence of the excess of the Lewis acid and potassium hydrogen difluoride, or BF<sub>3</sub>·OEt<sub>2</sub>-assisted conditions, was examined for the preparation of blocked carbohydrate-based oxazolines. A series of new oxazolines as valuable intermediates to prepare N-glycosyl amides, modified sugars and N-glycopeptides were synthesized in high yields, and screened for their inhibitory effects on proliferation of three human cancer cell lines. Of various 2-phenyl substituted N-furanosyl oxazolines evaluated, only the benzoyl-protected glucofuranosyl and ribofuranosyl oxazoline derivatives were found to exhibit good growth inhibition activities against two different cancer cell lines.

### Experimental section

*General information.* Column chromatography was performed on silica gel 60 H (70-230 mesh; Merck, Darmstadt, Germany), and thin-layer chromatography (TLC) on Merck silica gel aluminum 60 F<sub>254</sub> precoated plates. All commercially available reagents were used without further purification. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded in CDCl<sub>3</sub> and CD<sub>3</sub>OD with a Bruker Avance-500-DRX spectrometer at 500.13 and 126.76 MHz, respectively. <sup>1</sup>H and <sup>13</sup>C NMR chemical shifts ( $\delta$ , ppm) are relative to internal chloroform peak (7.26 ppm for <sup>1</sup>H and 77.0 for <sup>13</sup>C NMR). Splitting patterns were reported as following: s: singlet, d: doublet, t: triplet, m: multiplet. *J* values are reported in Hz. Optical rotations were measured with Autopol III automatic polarimeter. IR spectra were measured with on PerkinElmer Spectrum 100FT-IR spectrometer. Melting points were determined on a Boetius apparatus and were uncorrected. High resolution mass spectra (HRMS) were recorded on an Agilent Q-TOF 6550 Instrument (USA) using ESI (electrospray ionization).

#### *Synthesis of N-glycosyl oxazolines from protected pentofuranose 1,2-*O*-acetonides*

*a<sub>1</sub>. Synthesis 2-alkyl- $\alpha$ -D-pentofurano-[1,2-*d*]-2-oxazoline derivatives under the BF<sub>3</sub>·Et<sub>2</sub>O-KHF<sub>2</sub>-promoted conditions.* To a stirred solution of pentofuranose acetonide derivative (1.4 mmol) in anhy-



drous acetonitrile (8.6 ml) or benzonitrile (3.8 ml)  $\text{KHF}_2$  (4.8 mmol) and boron trifluoride diethyl etherate (1.42 ml, 10.3 mmol) were added successively. The resulting solution was stirred at room temperature for 18 h, and then the reaction mixture was poured into cooled 22.6 ml 1N aq NaOH. The aqueous phase was extracted with  $\text{CHCl}_3$  (3x100 ml). The combined organic extracts were washed with water, dried over anhydrous  $\text{Na}_2\text{SO}_4$ , and evaporated to dryness. Oxazolines **7-8**, **11-13** were prepared in 76-99% yields, and oxazolines **10**, **14**, **17** with 2-phenyl substituent were isolated in 97% yield after column chromatography on silica gel using for elution mixtures of hexane-ethylacetate and ethylacetate-methanol 6:1.

*a<sub>2</sub>. Synthesis 2-methyl- $\alpha$ -D-pentofurano-[1,2-d]-2-oxazoline derivatives under the  $\text{BF}_3\text{Et}_2\text{O}$ -promoted conditions.* To a stirred solution of xylofuranose acetonide derivative (0.2 mmol) in anhydrous acetonitrile (1.5 ml) boron trifluoride diethyl etherate (0.2 ml, 1.44 mmol) was added successively. The resulting solution was stirred at room temperature for 18 h, and then the reaction mixture was poured into cooled 5% aq.  $\text{NaHCO}_3$ . The aqueous phase was extracted with  $\text{CHCl}_3$  (3x50 ml). The combined organic extracts were washed with water, dried over anhydrous  $\text{Na}_2\text{SO}_4$ , and evaporated to dryness. Oxazolines **7**, **9** and **12** were prepared in 54-93% yields.

#### *Synthesis of N-glycosyl oxazolines from protected hexofuranose 1,2-O-acetonides*

*a<sub>1</sub>.* To a stirred solution of acylated glucofuranose or allofuranose acetonide (0.4 mmol) in anhydrous benzonitrile (3.8 ml) or acetonitrile (3.1 ml)  $\text{KHF}_2$  (1.95 mmol) and boron trifluoride diethyl etherate (0.45 ml, 3.3 mmol) were added successively. The reaction mixture was stirred at room temperature for 18 h, and then poured into cooled 7.3 ml 1N aq NaOH. The aqueous phase was extracted with  $\text{CHCl}_3$  (3x30 ml). The combined organic extracts were washed with water, dried over anhydrous  $\text{Na}_2\text{SO}_4$ , and evaporated. Oxazolines with 2-phenyl substituent were isolated by column chromatography on silica gel using for elution mixtures of hexane-ethylacetate 6:1, 4:1, 2:1, and ethylacetate or ethylacetate-methanol 6:1. Oxazolines **19-20**, **22-23** and **25**, **27** were prepared in 86-98% yields.

#### *2-Methyl-(5-O-benzoyl-3-O-p-toluenesulfonyl- $\alpha$ -D-xylofuran)-[1,2-d]-2-oxazoline (7).*

Yield (98%), a colorless oil (method *a<sub>1</sub>*).  $[\alpha]_D^{20}$  -44.4 (c 0.5,  $\text{CHCl}_3$ ). IR (film,  $\text{CCl}_4$ ):  $\nu$  1725, 1670, 1615, 1375, 1272  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  = 7.38-7.85 (m, 9H,  $\text{COC}_6\text{H}_5$  and  $\text{OSO}_2\text{C}_6\text{H}_4\text{CH}_3$ ), 6.09 (d, 1H,  $J_{1,2}$  = 5.4 Hz, H-1), 5.02 (d, 1H,  $J_{3,4}$  = 3.0 Hz, H-3), 4.86 (d, 1H, H-2), 4.33 (dd, 1H,  $J_{5,4}$  = 6.2,  $J_{5,5'}$  = 11.3 Hz, H-5), 4.22 (dd, 1H,  $J_{5',4}$  = 5.7 Hz, H-5'), 3.98-4.01 (m, 1H, H-4), 2.31 (s, 3H,  $\text{OSO}_2\text{C}_6\text{H}_4\text{CH}_3$ ), 1.96 (s, 3H,  $\text{NCH}_3$ ).  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ )  $\delta$  = 167.4 (CN), 164.9 (C=O,  $\text{COC}_6\text{H}_5$ ), 145.6, 133.4, 130.3, 129.2, 128.5, 127.6 ( $\text{COC}_6\text{H}_5$  and  $\text{OSO}_2\text{C}_6\text{H}_4\text{CH}_3$ ), 100.2 (C-1), 88.4 (C-4), 81.1, 74.2 (C-2, C-3), 60.3 (C-5), 21.0 ( $\text{OSO}_2\text{C}_6\text{H}_4\text{CH}_3$ ), 13.2 (NMe). HRMS (ESI<sup>+</sup>): m/z calcd for  $\text{C}_{21}\text{H}_{21}\text{NO}_7\text{S}$   $[\text{M}+\text{H}]^+$ : 432.1117, found 432.1120; and  $\text{C}_{21}\text{H}_{21}\text{NO}_7\text{SNa}$   $[\text{M}+\text{Na}]^+$ : 454.0936, found 454.0935.

#### *2-Methyl-(5-O-benzoyl-3-O-methanesulfonyl- $\alpha$ -D-xylofuran)-[1,2-d]-2-oxazoline (8).*

Yield (93%), a colorless oil (method *a<sub>1</sub>*).  $[\alpha]_D^{20}$  -35.1 (c 0.8,  $\text{CHCl}_3$ ). IR (film):  $\nu$  1722, 1675, 1357, 1275  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  = 7.47-8.09 (m, 5H,  $\text{COC}_6\text{H}_5$ ), 6.22 (d, 1H,  $J_{1,2}$  = 5.6 Hz, H-1), 5.23 (d, 1H,  $J_{3,4}$  = 3.1 Hz, H-3), 5.09 (d, 1H, H-2), 4.66 (dd, 1H,  $J_{5,4}$  = 6.3,  $J_{5,5'}$  = 11.8 Hz, H-5), 4.62 (dd, 1H,  $J_{5',4}$  = 3.4 Hz, H-5'), 4.13-4.16 (m, 1H, H-4), 3.16 (s, 3H,  $\text{OSO}_2\text{CH}_3$ ), 2.12 (s, 3H,  $\text{NCH}_3$ ).  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ )  $\delta$  = 168.8 (CN), 166.1 (C=O,  $\text{COC}_6\text{H}_5$ ), 133.5, 129.8, 129.3, 128.5, ( $\text{COC}_6\text{H}_5$ ), 100.8 (C-



1), 84.2 (C-4), 77.3, 75.1 (C-2, C-3), 60.8 (C-5), 38.5 (OSO<sub>2</sub>CH<sub>3</sub>), 13.9 (NMe). HRMS (ESI<sup>+</sup>): m/z calcd for C<sub>15</sub>H<sub>17</sub>NO<sub>7</sub>S [M+H]<sup>+</sup>: 356.0798, found 356.0791; and C<sub>21</sub>H<sub>21</sub>NO<sub>7</sub>Na [M+Na]<sup>+</sup>: 378.0610, found 378.0511.

*2-Methyl-(3,5-di-O-benzoyl-α-D-xylofuran)-[1,2-d]-2-oxazoline (9).*

Yield (96%), foam (method a<sub>1</sub>). [α]<sub>D</sub><sup>20</sup> -73.2 (c 1.0, CHCl<sub>3</sub>). IR (KBr): ν 1722, 1672, 1364, 1275, 1180 cm<sup>-1</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ = 7.39-8.04 (m, 10H, 2 x COC<sub>6</sub>H<sub>5</sub>), 6.21 (d, 1H, J<sub>1,2</sub> = 5.7 Hz, H-1), 5.59 (d, 1H, J<sub>3,4</sub> = 3.2 Hz, H-3), 4.86 (d, 1H, J<sub>2,1</sub> = 5.7 Hz, H-2), 4.64 (d, 2H, H-5, H-5'), 4.19-4.25 (m, 1H, H-4), 2.1 (s, 3H, NCH<sub>3</sub>). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ = 166.7 (CN), 166.1 and 165.2 (C=O, 2xCOC<sub>6</sub>H<sub>5</sub>), 140.2, 140.0, 131.3, 131.2, 128.9, 128.8, 128.7, 128.2 (2xCOC<sub>6</sub>H<sub>5</sub>), 100.8 (C-1), 84.6 (C-4), 76.3, 75.5 (C-2, C-3), 61.6 (C-5), 13.8 (NMe). HRMS (ESI<sup>+</sup>): m/z calcd for C<sub>21</sub>H<sub>19</sub>NO<sub>6</sub> [M+H]<sup>+</sup>: 382.1285, found 382.1287.

*2-Phenyl-(3,5-di-O-benzoyl-α-D-xylofuran)-[1,2-d]-2-oxazoline (10).*

Yield (97%), a colorless oil (method a<sub>1</sub>). [α]<sub>D</sub><sup>20</sup> -27.5 (c 1.0, CHCl<sub>3</sub>). IR (KBr): ν 1725, 1665, 1268, 1112 cm<sup>-1</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ = 7.42-8.13 (m, 15H, 2 x COC<sub>6</sub>H<sub>5</sub>, -N=C-C<sub>6</sub>H<sub>5</sub>), 6.52 (d, 1H, J<sub>1,2</sub> = 4.0 Hz, H-1), 5.79 (d, 1H, J<sub>3,4</sub> = 3.0 Hz, H-3), 5.15 (d, 1H, J<sub>2,1</sub> = 4.0 Hz, H-2), 4.74 (d, 2H, H-5, H-5'), 4.33-4.36 (m, 1H, H-4). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ = 167.0 (CN), 166.1 and 165.4 (C=O, 2xCOC<sub>6</sub>H<sub>5</sub>), 133.9, 133.2, 132.8, 129.9, 129.8, 129.2, 128.7, 128.6, 128.4 (2xCOC<sub>6</sub>H<sub>5</sub>, -N=C-C<sub>6</sub>H<sub>5</sub>), 100.8 (C-1), 84.8 (C-4), 76.4, 75.6 (C-2, C-3), 61.5 (C-5). HRMS (ESI<sup>+</sup>): m/z calcd for C<sub>26</sub>H<sub>21</sub>NO<sub>6</sub> [M+Na]<sup>+</sup>: 466.1261, found 466.1263.

*2-Ethyl-(3,5-di-O-benzoyl-α-D-xylofuran)-[1,2-d]-2-oxazoline (11).*

Yield (86%), foam, (method a<sub>1</sub>). [α]<sub>D</sub><sup>20</sup> - 36.3 (c 1.0, CHCl<sub>3</sub>). IR (KBr): ν 1724, 1670, 1363, 1275, 1182 cm<sup>-1</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ = 7.44-8.09 (m, 10H, 2 x COC<sub>6</sub>H<sub>5</sub>), 6.29 (d, 1H, J<sub>1,2</sub> = 5.7 Hz, H-1), 5.65 (d, 1H, J<sub>3,4</sub> = 3.2 Hz, H-3), 4.92 (d, 1H, J<sub>2,1</sub> = 5.7 Hz, H-2), 4.70 (d, 2H, H-5, H-5'), 4.21-4.28 (m, 1H, H-4), 2.45-2.49 (m, 2H, -N=C-CH<sub>2</sub>CH<sub>3</sub>), 1.29 (t, 3H, -N=C-CH<sub>2</sub>CH<sub>3</sub>). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ = 173.1 (CN), 166.2 and 165.3 (C=O, 2xCOC<sub>6</sub>H<sub>5</sub>), 133.8, 133.3, 129.9, 129.8, 129.5, 128.9, 128.7, 128.4 (2xCOC<sub>6</sub>H<sub>5</sub>), 100.6 (C-1), 84.5 (C-4), 76.3, 75.4 (C-2, C-3), 61.6 (C-5), 21.5 (N=C-CH<sub>2</sub>CH<sub>3</sub>), 10.2 (N=C-CH<sub>2</sub>CH<sub>3</sub>). HRMS (ESI<sup>+</sup>): m/z calcd for C<sub>21</sub>H<sub>21</sub>NO<sub>6</sub> [M+H]<sup>+</sup>: 396.1442, found 396.1446.

*2-Methyl-(3,5-O-isopropylidene-α-D-xylofuran)-[1,2-d]-2-oxazoline (12).*

Yield (76%), oil (method a<sub>1</sub>). [α]<sub>D</sub><sup>20</sup> +6.9 (c 1.0, CHCl<sub>3</sub>). IR (film): ν 2993, 2940, 1669, 1384, 1228, 1043 cm<sup>-1</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ = 6.10 (d, 1H, J<sub>1,2</sub> = 5.5 Hz, H-1), 4.65 (d, 1H, J<sub>2,1</sub> = 5.5 Hz, H-2), 4.30 (d, 1H, J<sub>3,4</sub> = 2.4 Hz, H-3), 4.09 (dd, 1H, J<sub>5,4</sub> = 2.5, J<sub>5,5'</sub> = 13.6 Hz, H-5), 4.07 (d, 1H, H-5'), 3.47-3.349 (m, 1H, H-4), 2.00 (s, 3H, NCH<sub>3</sub>), 1.42 and 1.36 [2 s, 3H, (CH<sub>3</sub>)<sub>2</sub>C-]. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ: 168.3 (CN), 101.3 (C-1), 97.7 [C-CH<sub>3</sub>]<sub>2</sub>, 85.9 (C-4), 72.9, 69.6 (C-2, C-3), 59.5 (C-5), 28.8 and 18.6 [(CH<sub>3</sub>)<sub>2</sub>C-], 13.7 (NMe). HRMS (ESI<sup>+</sup>): m/z calcd for C<sub>10</sub>H<sub>15</sub>NO<sub>4</sub> [M+H]<sup>+</sup>: 214.1074, found 214.1084.

*2-Methyl-(3,5-di-O-benzoyl-α-D-ribofuran)-[1,2-d]-2-oxazoline (13).*

Yield (99%), a colorless oil (method a<sub>1</sub>). [α]<sub>D</sub><sup>20</sup> +74.5 (c 1.0, CHCl<sub>3</sub>). IR (film): ν 1729, 1665, 1272, 1119 cm<sup>-1</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ = 7.40-8.08 (m, 10H, 2 x COC<sub>6</sub>H<sub>5</sub>), 6.17 (d, 1H, J<sub>1,2</sub> = 5.5 Hz, H-1), 5.22 (t, 1H, J<sub>2,1</sub> = 5.5, J<sub>2,3</sub> = 5.7 Hz, H-2), 5.16 (dd, 1H, J<sub>3,4</sub> = 9.0 Hz, H-3), 4.75 (dd, 1H, J<sub>5,4</sub> = 3.6, J<sub>5,5'</sub> = 12.0 Hz, H-5), 4.57 (dd, 1H, J<sub>5',4</sub> = 5.2 Hz, H-5'), 4.19-4.23 (m, 1H, H-4), 2.1 (s, 3H, NCH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ = 169.7 (CN), 166.1 and 165.5 (C=O, 2xCOC<sub>6</sub>H<sub>5</sub>), 133.6, 133.2, 129.8, 129.7, 129.4,

128.8, 128.5, 128.3 (2xCOC<sub>6</sub>H<sub>5</sub>), 100.6 (C-1), 78.5 (C-4), 74.1, 74.0 (C-2, C-3), 63.0 (C-5), 13.8 (NMe). HRMS (ESI<sup>+</sup>): m/z calcd for C<sub>21</sub>H<sub>19</sub>NO<sub>6</sub> [M+H]<sup>+</sup>: 382.1285, found 382.1287.

*2-Phenyl-(3,5-di-O-benzoyl-α-D-ribofuran)-[1,2-d]-2-oxazoline (14).*

Yield (97%), a white solid (method a<sub>1</sub>). M.p. 128-129 °C. [α]<sub>D</sub><sup>20</sup>+113.8 (c 1.0, CHCl<sub>3</sub>). IR (KBr): ν 1739, 1716, 1646, 1277, 1101 cm<sup>-1</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ = 7.35-8.04 (m, 15H, 2 x COC<sub>6</sub>H<sub>5</sub>, -N=C-C<sub>6</sub>H<sub>5</sub>), 6.37 (d, 1H, J<sub>1,2</sub>=5.6 Hz, H-1), 5.38 (t, 1H, J<sub>3,2</sub>=5.7 Hz, H-2), 5.24 (d, 1H, J<sub>3,4</sub>=J<sub>3,2</sub>=5.9 Hz, H-3), 4.72 (dd, 1H, J<sub>5,4</sub>=4.7, J<sub>5,5'</sub>=12.1 Hz, H-5), 4.55 (dd, 1H, J<sub>5',4</sub>=4.7 Hz, H-5'), 4.20-4.24 (m, 1H, H-4). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ = 167.5 (CN), 166.1 and 165.7 (C=O, 2xCOC<sub>6</sub>H<sub>5</sub>), 133.6, 133.1, 132.5, 129.8, 129.7, 129.4, 128.9, 128.8, 128.5 (2xCOC<sub>6</sub>H<sub>5</sub>, -N=C-C<sub>6</sub>H<sub>5</sub>), 100.8 (C-1), 78.4 (C-4), 74.1, 74.09 (C-2, C-3), 63.0 (C-5). HRMS (ESI<sup>+</sup>): m/z calcd for C<sub>26</sub>H<sub>21</sub>NO<sub>6</sub> [M+Na]<sup>+</sup>: 466.1261, found 466.1264.

*2-Methyl-(3,5-di-O-benzoyl-β-D-arabinofuran)-[1,2-d]-2-oxazoline(16).*

Yield (99%), a colorless oil (method a<sub>1</sub>). [α]<sub>D</sub><sup>20</sup>-36.1 (c 1.0, CHCl<sub>3</sub>). IR (KBr): ν 1725, 1669, 1321, 1269, 1108 cm<sup>-1</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ = 7.41-8.06 (m, 10H, 2 x COC<sub>6</sub>H<sub>5</sub>), 6.14 (d, 1H, J<sub>1,2</sub>=5.4 Hz, H-1), 5.51 (br.d, 1H, J<sub>3,4</sub>=2.5, J<sub>3,2</sub>=1.2 Hz, H-3), 4.98 (br. d, 1H, J<sub>2,1</sub>=5.5 Hz, H-2), 4.54-4.57 (m, 1H, H-4), 4.39 (dd, 1H, J<sub>5,4</sub>=6.2, J<sub>5,5'</sub>=11.7 Hz, H-5), 4.36 (dd, 1H, J<sub>5',4</sub>=3.9 Hz, H-5'), 2.07 (s, 3H, NCH<sub>3</sub>). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ = 168.7 (CN), 166.1 and 165.4 (C=O, 2xCOC<sub>6</sub>H<sub>5</sub>), 133.7, 133.1, 129.8, 129.8, 129.6, 128.8, 128.5, 128.3 (2xCOC<sub>6</sub>H<sub>5</sub>), 101.8 (C-1), 86.4 (C-4), 80.7, 79.0 (C-2, C-3), 63.7 (C-5), 14.3 (NMe). HRMS (ESI<sup>+</sup>): m/z calcd for C<sub>21</sub>H<sub>19</sub>NO<sub>6</sub> [M+H]<sup>+</sup>: 382.1285, found 382.1287.

*2-Phenyl-(3,5-di-O-benzoyl-β-D-arabinofuran)-[1,2-d]-2-oxazoline (17).*

Yield (97%), a colorless oil (method a<sub>1</sub>). [α]<sub>D</sub><sup>20</sup>-8.5 (c 1.0, CHCl<sub>3</sub>). IR (film): ν 1721, 1642, 1269, 1109 cm<sup>-1</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ = 7.30-8.14 (m, 15H, 2 x COC<sub>6</sub>H<sub>5</sub>, -N=C-C<sub>6</sub>H<sub>5</sub>), 6.46 (d, 1H, J<sub>1,2</sub>=5.7 Hz, H-1), 5.76 (d, 1H, J<sub>3,4</sub>=2.6 Hz, H-3), 5.29 (d, 1H, J<sub>2,1</sub>=5.7 Hz, H-2), 4.65-4.68 (m, 1H, H-4), 4.48 (dd, 1H, J<sub>5,4</sub>=5.8, J<sub>5,5'</sub>=11.6 Hz, H-5), 4.38 (dd, 1H, J<sub>5',4</sub>=6.4 Hz, H-5'). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ = 166.9 (CN), 166.1 and 165.5 (C=O, 2xCOC<sub>6</sub>H<sub>5</sub>), 133.8, 133.1, 132.8, 129.9, 129.8, 129.2, 128.7, 128.6, 128.3 (2xCOC<sub>6</sub>H<sub>5</sub>, -N=C-C<sub>6</sub>H<sub>5</sub>), 100.9 (C-1), 86.7 (C-4), 81.4, 79.3 (C-2, C-3), 63.8 (C-5). HRMS (ESI<sup>+</sup>): m/z calcd for C<sub>26</sub>H<sub>21</sub>NO<sub>6</sub> [M+Na]<sup>+</sup>: 466.1261, found 466.1265.

*2-Methyl-(3,5,6-tri-O-benzoyl-α-D-glucofuran)-[1,2-d]-2-oxazoline (19).*

Yield (93%), a colorless oil (method a<sub>1</sub>). [α]<sub>D</sub><sup>20</sup>-173.0 (c 1.0, CHCl<sub>3</sub>). IR (film): ν 1725, 1667, 1375, 1266 cm<sup>-1</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ = 7.40-8.04 (m, 15H, 3 x COC<sub>6</sub>H<sub>5</sub>), 6.26 (d, 1H, J<sub>1,2</sub>=5.6 Hz, H-1), 5.90-5.93 (m, 1H, H-5), 5.62 (dd, 1H, J<sub>3,4</sub>=3.1 Hz, H-3), 5.02 (dd, 1H, H-6), 4.90 (d, 1H, H-2), 4.63 (dd, 1H, H-6'), 4.27 (dd, 1H, H-4), 2.18 (s, 3H, NCH<sub>3</sub>). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ = 169.04 (CN), 166.11, 165.3 and 165.1 (C=O, 3xCOC<sub>6</sub>H<sub>5</sub>), 133.69, 133.27, 133.06, 131.18, 129.9, 129.73, 129.68, 128.56 128.37 (3xCOC<sub>6</sub>H<sub>5</sub>), 100.88 (C-1), 84.56, 75.71, 75.64, 75.51 (C-4, C-5, C-2, C-3), 64.25 (C-6), 13.9 (NMe). HRMS (ESI<sup>+</sup>): m/z calcd for C<sub>29</sub>H<sub>25</sub>NO<sub>8</sub> [M+Na]<sup>+</sup>: 538.1478, found 538.1453.

*2-Phenyl-(3,5,6-tri-O-benzoyl-α-D-glucofuran)-[1,2-d]-2-oxazoline (20).*

Yield (92%), a colorless oil (method a<sub>1</sub>). [α]<sub>D</sub><sup>20</sup>-34.6 (c 1.0, CHCl<sub>3</sub>). IR (KBr): ν 1728, 1646, 1268, 1102 cm<sup>-1</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ = 7.36-8.15 (m, 20H, 2 x COC<sub>6</sub>H<sub>5</sub>, -N=C-C<sub>6</sub>H<sub>5</sub>), 6.52 (d, 1H, J<sub>1,2</sub>=5.5 Hz, H-1), 5.95-5.99 (m, 1H, H-5), 5.75 (d, 1H, J<sub>3,4</sub>=3.0 Hz, H-3), 5.13 (d, 1H, J<sub>2,1</sub>=5.5 Hz, H-2), 5.06 (dd, 1H, J<sub>6,5</sub>=5.8, J<sub>6,6'</sub>=11.6 Hz, H-6), 4.65 (dd, 1H, J<sub>6,5</sub>=5.4 Hz, H-6'), 4.36 (dd, 1H, H-4). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ = 166.9 (CN), 166.0, 165.3 and 165.0 (C=O, 3xCOC<sub>6</sub>H<sub>5</sub>), 133.6, 133.1,

132.9, 132.7, 129.8, 129.6, 128.6, 128.5, 128.2 (3xCOC<sub>6</sub>H<sub>5</sub>, -N=C-C<sub>6</sub>H<sub>5</sub>), 100.9 (C-1), 84.8, 75.6, 75.6, 68.4 (C-5, C-4, C-2, C-3), 64.2 (C-6). HRMS (ESI<sup>+</sup>): m/z calcd for C<sub>34</sub>H<sub>27</sub>NO<sub>8</sub> [M+Na]<sup>+</sup>: 600.1634, found 600.1630.

*2-Methyl-(3,5,6-tri-O-acetyl-α-D-glucofurano)-[1,2-d]-2-oxazoline (22).*

Yield (95%), a colorless oil (method a<sub>1</sub>). [α]<sub>D</sub><sup>20</sup> +7.2 (c 1.0, CHCl<sub>3</sub>). IR (film): ν 1743, 1662, 1375, 1243 cm<sup>-1</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ = 6.07 (d, 1H, J<sub>1,2</sub> = 5.6 Hz, H-1), 5.34 (br.s, 1H, H-3), 5.23-5.26 (m, 1H, H-5), 4.63 (d, 1H, J<sub>3,4</sub> = 3.1 Hz, H-2), 4.54 (dm, 1H, H-4), 4.04 (dd, 1H, H-6), 3.82 (dd, 1H, H-6'), 2.06, 2.05, 2.02, and 1.97 (4s, 3H, 3x COCH<sub>3</sub>, NCH<sub>3</sub>). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ = 170.6 (CN), 169.6, 169.6 and 168.8 (C=O, 3xCOCH<sub>3</sub>), 100.9 (C-1), 84.5, 75.2, 74.3, 67.5 (C-4, C-5, C-2, C-3), 63.4 (C-6), 20.8 and 20.7 (3xCOCH<sub>3</sub>), 13.9 (NMe). HRMS (ESI<sup>+</sup>): m/z calcd for C<sub>14</sub>H<sub>19</sub>NO<sub>8</sub> [M+Na]<sup>+</sup>: 352.1003, found 352.1006.

*2-Phenyl-(3,5,6-tri-O-acetyl-α-D-glucofurano)-[1,2-d]-2-oxazoline (23).*

Yield (92%), a white solid (method a<sub>1</sub>). M.p. 169-172 °C. [α]<sub>D</sub><sup>20</sup> +25.0 (c 1.0, CHCl<sub>3</sub>). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ = 7.43-8.02 (m, 5H, Ph), 6.33 (d, 1H, J<sub>1,2</sub> = 5.5 Hz, H-1), 5.49 (d, 1H, J<sub>3,2</sub> = 3.0 Hz, H-3), 5.31 (ddd, 1H, H-5), 4.86 (d, 1H, J<sub>2,1</sub> = 5.5 Hz, H-2), 4.60 (dd, 1H, J<sub>6,5</sub> = 2.1, J<sub>6,6'</sub> = 12.3 Hz, H-6), 4.08 (dd, 1H, J<sub>6,5</sub> = 5.8, H-6'), 3.91 (dd, 1H, H-4), 2.11, 2.01 and 1.99 (3s, 3H, 3xCOCH<sub>3</sub>). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ: 170.7 (-C=N), 169.75, 169.71 and 166.6 (C=O, 3xCOCH<sub>3</sub>), 113.3, 129.1, 128.6, 115.9 (Ph-C=N-), 101.1 (C-1), 84.5, 75.4, 74.5, 67.5 (C-4, C-5, C-2, C-3), 63.4 (C-6), 20.81 and 20.76 (3xCOCH<sub>3</sub>). HRMS (ESI<sup>+</sup>): m/z calcd for C<sub>18</sub>H<sub>21</sub>NO<sub>8</sub> [M+Na]<sup>+</sup>: 402.1003, found 402.1008.

*2-Phenyl-(3,5,6-tri-O-benzoyl-α-D-allofurano)-[1,2-d]-2-oxazoline (25).*

Yield (86%), a colorless oil (method a<sub>1</sub>). [α]<sub>D</sub><sup>20</sup> +58.5 (c 1.0, CHCl<sub>3</sub>). IR (film): ν 1728, 1649, 1265, 1118 cm<sup>-1</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ = 7.29-8.00 (m, 15H, 3 x COC<sub>6</sub>H<sub>5</sub>), 6.40 (d, 1H, J<sub>1,2</sub> = 5.6 Hz, H-1), 5.87-5.90 (m, 1H, H-5), 5.43-5.47 (m, 2H, H-2 and H-3), 4.88 (dd, 1H, J<sub>6,5</sub> = 3.3, J<sub>6,6'</sub> = 12.1 Hz, H-6), 4.68 (dd, 1H, J<sub>6,5</sub> = 6.8 Hz, H-6'), 4.27 (dd, 1H, H-4). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ = 166.8 (-C=N), 166.1, 165.54 and 165.5 (C=O, 3xCOC<sub>6</sub>H<sub>5</sub>, C<sub>6</sub>H<sub>5</sub>), 133.4, 133.2, 133.1, 132.6, 129.8, 129.7, 129.0, 128.5, 128.4, 128.3, 128.2 (3xCOC<sub>6</sub>H<sub>5</sub>, Ph-C=N-), 100.8 (C-1), 78.6, 75.1, 74.7, 71.2 (C-4, C-5, C-2, C-3), 63.4 (C-6). HRMS (ESI<sup>+</sup>): m/z calcd for C<sub>34</sub>H<sub>27</sub>NO<sub>8</sub> [M+H]<sup>+</sup>: 578.1810, found 578.1816; [M+Na]<sup>+</sup>: 600.1634, found 600.1637.

*2-Methyl-(3,5,6-tri-O-acetyl-α-D-allofurano)-[1,2-d]-2-oxazoline (27).*

Yield (98%), a colorless oil (method a<sub>1</sub>). [α]<sub>D</sub><sup>20</sup> +107.2 (c 1.0, CHCl<sub>3</sub>). IR (film): ν 17440, 1667, 1375, 1247 cm<sup>-1</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ = 6.01 (d, 1H, J<sub>1,2</sub> = 5.6 Hz, H-1), 5.34 (dm, 1H, H-5), 5.02 (t, 1H, J<sub>2,3</sub> = 5.8 Hz, H-2), 4.94 (dd, 1H, H-3), 4.41 (dd, 1H, H-4), 4.14 (dd, 1H, H-6), 3.80 (dd, 1H, H-6'), 2.16, 2.11, 2.10, and 2.08 (4s, 3H, 3x COCH<sub>3</sub>, NCH<sub>3</sub>). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ = 170.5 (CN), 169.8, 169.7 and 169.6 (C=O, 3xCOCH<sub>3</sub>), 100.4 (C-1), 78.2, 74.5, 73.9, 70.0 (C-4, C-5, C-2, C-3), 62.3 (C-6), 20.8, 20.7 and 20.4 (3xCOCH<sub>3</sub>), 13.9 (NMe). HRMS (ESI<sup>+</sup>): m/z calcd for C<sub>14</sub>H<sub>19</sub>NO<sub>8</sub> [M+Na]<sup>+</sup>: 352.1003, found 352.1004.

*Synthesis of 2-O-isopropyl-3-O-p-toluenesulfonyl-5-O-benzoylxylitol (30).*

To a stirred solution of acetone **3** (147 mg, 0.33 mmol) in anhydrous acetonitrile (1.9 ml) KHF<sub>2</sub> (103 mg, 1.32 mmol), NaBH<sub>4</sub> (59 mg, 1.5 mmol) and then boron trifluoride diethyl etherate (1.42 ml, 11.38 mmol) were added successively. The reaction mixture was stirred at room temperature for 18 h, and then was gradually poured into cooled 5% NaHCO<sub>3</sub>. The aqueous phase was extracted with CHCl<sub>3</sub> (3x30 ml).

The combined organic extracts were washed water, dried over anhydrous  $\text{Na}_2\text{SO}_4$ , and evaporated to dryness. The residue was chromatographed on silica gel, using for elution a mixture of hexane-ethylacetate 6:1 and 3:1, and 1:2 as the eluent to give the starting acetone **3** (38 mg, 26%) and the xylitol derivative **30** (59 mg, 40%) as a colorless oil.  $[\alpha]_D^{20} +1.4$  (c 0.5,  $\text{CHCl}_3$ ).  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  = 7.30-8.03 (m, 9H,  $\text{COC}_6\text{H}_5$  and  $\text{OSO}_2\text{C}_6\text{H}_4\text{CH}_3$ ), 4.84 (dd, 1H), 4.31-4.38 (m, 2H), 3.90-3.97 (m, 3H), 3.82-3.91 (m, 2H), 2.41 (s, 3H,  $\text{OSO}_2\text{C}_6\text{H}_4\text{CH}_3$ ), 1.22 [d, 3H,  $(\text{CH}_3)\text{CH}$ -], 1.21 [d, 3H,  $(\text{CH}_3)\text{CH}$ -].  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ )  $\delta$  = 165.9 (C=O,  $\text{COC}_6\text{H}_5$ ), 145.4, 133.3, 130.0, 129.8, 129.7, 128.5 ( $\text{COC}_6\text{H}_5$  and  $\text{OSO}_2\text{C}_6\text{H}_4\text{CH}_3$ ), 78.3, 75.5, 72.2, 65.5, 64.5 ( $-\text{CH}_2\text{OBz}$ ), 59.9 ( $-\text{CH}_2\text{OH}$ ), 22.8 [ $(\text{CH}_3)_2\text{CH}$ -], 22.7 [ $(\text{CH}_3)_2\text{CH}$ -], 21.7 ( $\text{OSO}_2\text{C}_6\text{H}_4\text{CH}_3$ ). HRMS ( $\text{ESI}^+$ ):  $m/z$  calcd for  $\text{C}_{22}\text{H}_{22}\text{O}_8\text{SNa}$   $[\text{M}+\text{Na}]^+$ : 475.1403, found 475.1391.

*Synthesis of 2-O-isopropyl-3-O-p-toluenesulfonyl-1,4,5-tri-O-benzoylxylitol (31).*

To a stirred solution of xylitol derivative **30** (45 mg, 0.099 mmol) in anhydrous pyridine (2 ml)  $\text{BzCl}$  (0.068 ml, 0.57 mmol) was added at 0 °C and then the reaction mixture was stirred for 48 h at room temperature, diluted with  $\text{CH}_2\text{Cl}_2$  and poured into cold 5% aq  $\text{NaHCO}_3$ . The aqueous phase was extracted with  $\text{CH}_2\text{Cl}_2$  (3x50 ml), the combined organic extracts were washed with water, dried and evaporated. The residue was chromatographed on a silica gel, using for elution a mixture of hexane-ethylacetate 6:1, 5:1, and chloroform to give (42.7 mg, 65%) of protected xylitol derivative **31** as a colorless oil.  $[\alpha]_D^{20} -17.8$  (c 0.79,  $\text{CHCl}_3$ ).  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  = 7.40-8.18 (m, 15H,  $3\times\text{COC}_6\text{H}_5$ ), 7.77 and 7.11 (2d, 4H,  $\text{OSO}_2\text{C}_6\text{H}_4\text{CH}_3$ ), 5.91 (q, 1H, H-4), 5.26 (dd, 1H, H-3), 4.64 (dd, 1H, H-5), 4.60 (dd, 1H, H-5'), 4.54 (dd, 1H, H-1), 4.47 (dd, 1H, H-1'), 4.19-4.22 (m, 1H, H-2), 3.89-3.94 [m, 1H,  $(\text{CH}_3)_2\text{CH}$ -], 2.30 (s, 3H,  $\text{OSO}_2\text{C}_6\text{H}_4\text{CH}_3$ ), 1.25 [d, 3H,  $(\text{CH}_3)\text{CH}$ -], 1.21 [d, 3H,  $(\text{CH}_3)\text{CH}$ -].  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ )  $\delta$  = 166.1, 165.8, and 165.3 (C=O,  $3\times\text{COC}_6\text{H}_5$ ), 145.0, 133.8, 133.4, 133.2, 133.16, 130.2, 130.0, 129.8 ( $\text{COC}_6\text{H}_5$  and  $\text{OSO}_2\text{C}_6\text{H}_4\text{CH}_3$ ), 77.9, 73.5, 72.4, 69.6, 62.7, 62.6, 22.9 [ $(\text{CH}_3)_2\text{CH}$ -], 22.2 [ $(\text{CH}_3)_2\text{CH}$ -], 21.6 ( $\text{OSO}_2\text{C}_6\text{H}_4\text{CH}_3$ ). HRMS ( $\text{ESI}^+$ ):  $m/z$  calcd for  $\text{C}_{36}\text{H}_{36}\text{O}_{10}\text{SNa}$   $[\text{M}+\text{Na}]^+$ : 683.1927, found 683.1929.

*Synthesis of 2-methyl-(5-O-benzoyl- $\alpha$ -D-xylofuranose)-[1,2-d]-2-oxazoline (49) from 5-O-benzoyl-D-xylofuranose (47).*

b<sub>1</sub>. To a stirred solution of 5-O-benzoyl xylofuranose **47** (49 mg, 0.19 mmol) in anhydrous acetonitrile (2.5 ml)  $\text{KHF}_2$  (57 mg, 0.89 mol) and boron trifluoride diethyl etherate (0.14 ml, 1.10 mmol) were added successively. The reaction mixture was stirred at room temperature for 3 h, and then poured into cooled 5% aq  $\text{NaHCO}_3$ . The aqueous phase was extracted with  $\text{CHCl}_3$  (3x50 ml). The combined organic extracts were washed with water, dried over anhydrous  $\text{Na}_2\text{SO}_4$ , and evaporated to dryness. The oxazoline **49** (40 mg, 75%) was prepared as a colorless oil.  $[\alpha]_D^{20} -15.9$  (c 0.56,  $\text{CHCl}_3$ ). M.p. 63-65 °C (crystallized under storing).  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  = 7.49-8.09 (m, 5H,  $\text{COC}_6\text{H}_5$ ), 6.14 (d, 1H,  $J_{1,2} = 5.5$  Hz, H-1), 4.86 (dd, 1H,  $J_{5,4} = 7.4$  Hz,  $J_{5,5'} = 11.6$  Hz, H-5), 4.82 (d, 1H,  $J_{2,1} = 5.6$  Hz, H-2), 4.47 (dd, 1H,  $J_{5',4} = 5.1$  Hz, H-5'), 4.27 (d, 1H,  $J_{3,4} = 2.3$  Hz, H-3), 3.86-3.89 (m, 1H, H-4), 2.09 (s, 3H,  $\text{NCH}_3$ ).  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ )  $\delta$  = 168.9 (CN), 167.3 (C=O,  $\text{COC}_6\text{H}_5$ ), 100.0 (C-1), 86.6 (C-4), 76.7, 74.1 (C-2, C-3), 61.3 (C-5), 13.9 (NMe). HRMS ( $\text{ESI}^+$ ):  $m/z$  calcd for  $\text{C}_{14}\text{H}_{15}\text{NO}_5$   $[\text{M}+\text{H}]^+$ : 278.1028, found 278.1025.

*Synthesis of 2-methyl-(3,5-di-O-benzoyl- $\alpha$ -D-ribofuranose)-[1,2-d]-2-oxazoline (13) from 1,3,5-tri-O-benzoyl- $\alpha$ -D-ribofuranose (50).*

b<sub>2</sub>. To a stirred solution of 1,3,5-tri-O-benzoyl- $\alpha$ -D-ribofuranose (**50**) (250 mg, 0.54 mmol) in anhydrous acetonitrile (10.0 ml)  $\text{KHF}_2$  (156 mg, 1.99 mmol) and boron trifluoride diethyl etherate (0.39 ml, 3.08 mmol) were added successively. The reaction mixture solution was stirred at room temperature for 3.5 h,

and then poured into cooled 1N aq NaOH. The oxazoline **13** (204 mg, 99%) was prepared as a colorless oil after the work-up.

c<sub>2</sub>. To a stirred solution of ribofuranose derivative **50** (100 mg, 0.22 mmol) in anhydrous acetonitrile (4.0 ml) boron trifluoride diethyl etherate (0.16 ml, 1.26 mmol) was added. The reaction mixture solution was stirred at room temperature for 3.5 h, and then poured into cooled 2.7 ml 1N aq NaOH. The oxazoline **13** (90 mg) as yellowish oil was prepared in 65% yield estimated by <sup>1</sup>H NMR in CDCl<sub>3</sub>.

#### *2-Phenyl-(β-D-arabinofurano)-[1,2-d]-2-oxazoline (51).*

3,5-Di-O-benzoyl oxazoline derivative **17** (95 mg, 0.21 mmol) was dissolved in 7 ml methanol saturated at 0 °C with ammonia, then reaction mixture was left for 14 h at room temperature and evaporated to dryness. The residue was chromatographed on a silica gel, using for elution chloroform, chloroform-methanol 15:1, 10:1 and 6:1 to give (47 mg, 93%) of the oxazoline **51** as oil.  $[\alpha]_D^{20}$  -18.7 (c 0.56, MeOH). <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD)  $\delta$  = 7.99-7.49 (m, 5H, -N=C-C<sub>6</sub>H<sub>5</sub>), 6.18 (d, 1H,  $J_{1,2}$  = 6.2 Hz, H-1), 5.03 (dd, 1H,  $J_{2,3}$  = 1.3 Hz, H-2), 4.36 (br.d, 1H, H-3), 3.98-4.01 (m, 1H, H-4), 3.49 (dd, 1H,  $J_{5,4}$  = 6.0,  $J_{5,5'}$  = 11.8 Hz, H-5), 3.44 (dd, 1H,  $J_{5',4}$  = 6.1 Hz, H-5'). <sup>13</sup>C NMR (126 MHz, CD<sub>3</sub>OD)  $\delta$  = 168.74 (CN), 134.08, 130.01 and 128.04 (N-C<sub>6</sub>H<sub>5</sub>), 101.98 (C-1), 90.85 (C-4), 87.31, 77.86 (C-2, C-3), 62.93 (C-5). HRMS (ESI<sup>+</sup>): m/z calcd for C<sub>12</sub>H<sub>13</sub>NO<sub>4</sub> [M+H]<sup>+</sup>: 236.0923, found 236.0927.

#### *2-Phenyl-(3,5-di-O-acetyl β-D-arabinofurano)-[1,2-d]-2-oxazoline (52).*

The oxazoline **51** (20 mg, 0.085 mmol) was dissolved in 1.7 ml anhydrous pyridine, acetic anhydride (0.04 ml, 0.42 mmol) was added, then reaction mixture was stirred for 48 h at room temperature and then poured into a mixture of ice and water. The aqueous phase was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3x20 ml). The combined organic extracts were washed with water, dried over anh. Na<sub>2</sub>SO<sub>4</sub>, and evaporated to dryness. The residue was chromatographed on a silica gel, using for elution elution mixtures of ethylacetate-petroleum ether to give (22 mg, 80%) of the oxazoline **52** as oil.  $[\alpha]_D^{20}$  -4.6 (c 0.3, CHCl<sub>3</sub>). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  = 7.42-8.03 (m, 5H, -N=C-C<sub>6</sub>H<sub>5</sub>), 6.30 (d, 1H,  $J_{1,2}$  = 6.2 Hz, H-1), 5.32 (br.d, 1H, H-3), 5.04 (br.d, 1H,  $J_{2,3}$  = 1.3,  $J_{2,1}$  = 6.2 Hz, H-2), 4.26-4.33 (m, 1H, H-4), 4.06 (dd, 1H,  $J_{5,4}$  = 5.9,  $J_{5,5'}$  = 11.8 Hz, H-5), 4.02 (dd, 1H,  $J_{5',4}$  = 6.1 Hz, H-5'), 2.15 and 1.89 (2s, 3H, -COCH<sub>3</sub>). <sup>13</sup>C NMR (126 MHz, CD<sub>3</sub>OD)  $\delta$  = 170.6, 169.9 and 166.5 (2-COCH<sub>3</sub> and CN), 132.7, 129.1, 128.8, 128.6 (N-C<sub>6</sub>H<sub>5</sub>), 102.2 (C-1), 86.1 (C-4), 81.2, 78.8 (C-2, C-3), 62.5 (C-5), 20.9 and 20.6 (2xCOCH<sub>3</sub>). HRMS (ESI<sup>+</sup>): m/z calcd for C<sub>16</sub>H<sub>17</sub>NO<sub>6</sub> [M+Na]<sup>+</sup>: 343.0940, found 343.0945.

#### *Biological assays of antiproliferative activity*

##### *Cell culturing*

Anti-proliferative activities of newly synthesized compounds were tested against myelogenous leukemia (K562), cervical carcinoma (Hela), breast carcinoma (MCF-7) in comparison with 5-fluorouracil as the positive control. Human cell lines were obtained from the Institute of Cytology, Russian Academy of Sciences. Human cell lines were cultured as monolayers and maintained in Eagle's medium (DMEM) supplemented with 10% foetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml amoxicillin, 100 µg/ml streptomycin in a humidified atmosphere of 5% CO<sub>2</sub> at 37 °C. Stock solutions of compounds were prepared in DMSO and kept at -20°C. Controls were added with the final concentration of DMSO (0.01%).

##### *Proliferation assays*

The cytotoxic effects on human cancer cells were assessed after 72 h incubation of sugar oxazoline derivative in concentrations 0.1 - 50 µM with the cell culture in a 96-well flat-bottomed plate at 37 °C



under conditions of 5% CO<sub>2</sub> and 95% air humidity using resazurin assay with triplicate experiments. Aliquots of resazurin solution (10 μL) was added to each well and incubated for 3 h at 37 °C. In all experiments, DMSO controls were included. Fluorescence resorufin measurements were performed on a multimodal absorbance fluorimeter Infinite® 200 PRO (Tecan, Switzerland) at an excitation wavelength of 530 nm and an emission wavelength of 590 nm. IC<sub>50</sub> values for each compound were calculated from the cell growth inhibition curves obtained from the treatments done with increasing concentrations.

### Conflict of interest

There are no conflicts to declare.

### Acknowledgements

This study was supported by grants from Belarusian Fond Fundamental Investigations (X-16-048) and FOI «Chemical processes, reagents and technologies, bioregulators and bioorgchemistry», s/p «Chemical foundations of life activity processes» (Bioorgchemisrty 2.3.2.2).

### References

1. Cordero F.M., Lascialfori L., Machetti F., (2021) Five-membered ring systems with O and N atoms. In *Progress, in Heterocycl. Chem.* Gribble G.W., Joule J.A. Eds.; Elsevier.; 33, 311-340. <https://doi.org/10.1016/B978-0-323-98410-2.00011-4>.
2. Gant T.G., Meyers A.I., (1994) The CHEMISTRY of 2-OXAZOLINES (1985-PRESENT), *Tetrahedron*. 50, 2297-2360. [https://doi.org/10.1016/S0040-4020\(01\)86953-2](https://doi.org/10.1016/S0040-4020(01)86953-2).
3. Fairbanks A.J., (2018) Synthetic and semi-synthetic approaches to unprotected N-glycan oxazoline. *Beilstein J. Org. Chem.* 14, 416-429. <https://doi.org/10.3762/bjoc.14.30>.
4. Parsons T.B., Patel M.K., Vocadlo D.J., Boraston A.B., Fairbanks A.J., (2010) Streptococcus pneumoniae endohexosaminidase D: feasibility of using N-glycan oxazoline donors for synthetic glycosylation of a GlcNAc-asparagine acceptor, *Org. Biomol. Chem.* 8, 1861-1868. <https://doi.org/10.1039/B926078A>.
5. Koda Y., Terashima T., Ouchi M., (2019) Unnatural Oligoaminosaccharides with N-1,2-Glycosidic Bonds Prepared by Cationic Ring-Opening Polymerization of 2-Oxazoline-Based Heterobicyclic Sugar Monomers, *ACS Macro Lett.* 8, 1456-460. <https://doi.org/10.1021/acsmacrolett.9b00674>.
6. Damkaci F., DeShong P., (2003) Stereoselective Synthesis of α- and β-Glycosamide Derivatives from Glycopyranosyl Azides via Isooxazoline Intermediates, *J. Am. Chem. Soc.* 125, 4408-4409. <https://doi.org/10.1021/ja028694u>.
7. Blanco J.L.J., Rubio E.M., Mellet C.O., Fernandez J.M.G., (2004) Synthesis of Sugar Oxazolines by Intramolecular Ritter-Like Reaction of D-Fructose Precursors, *Synlett.* 12, 2230-2232. <https://doi.org/10.1055/s-2004-830891>.
8. Vangala M., Shinde G.P., (2015) Synthesis of D-fructose-derived spirocyclic 2-substituted-2-oxazoline ribosides, *Beilstein J. Org. Chem.* 11, 2289-2296. <https://doi.org/10.3762/bjoc.11.249>.
9. Reid E.M., Vigneau E.S., Gratia S.S., Mazzabadi C.H., De Castra H., (2012) One-Pot Synthesis of N-Glycooxazolines, N-Glycoaminooxazolines, and N-Glycothiazolines from Glycals. *Eur. Org. Chem.* 17, 3295-3303. <https://doi.org/10.1002/ejoc.201200130>.
10. Andreini M., Anderluth M., Audfray A., Bernardi A., Imberty A., (2010) Monovalent and bivalent N



- fucosyl amides as high affinity ligands for *Pseudomonas aeruginosa* PA-IIL lectin. *Carbohydr. Res.* 345, 1400-1407. <https://doi.org/10.1016/j.carres.2010.03.012>
11. Gordon D.M., Danishefsky S.J., (1991) Ritter-like Reactions of 1,2-Anhydropyranose Derivatives, *J. Org. Chem.* 56, 3713-3715. <https://doi.org/10.1021/jo00011a050>.
  12. Blanco J.L.J., Sylla B., Mellet C.O., Fernandez J M.G., (2007) Synthesis of  $\alpha$ - and  $\beta$ -Glycosyl Isothiocyanates via Oxazoline Intermediates, *J. Org. Chem.* 72, 4547-4555. <https://doi.org/10.1021/jo062419z>.
  13. Glorgydeák Z., Hadady Z., Felföldi N., Krakomperger A., Nagy V., et al. (2004) Synthesis of N-( $\beta$ -D-glucopyranosyl)- and N-(2-acetamido-2-deoxy- $\beta$ -D-glucopyranosyl) amides as inhibitors of glycogen phosphorylase, *Bioorg. & Med. Chem.* 12, 4861-4820. <https://doi.org/10.1061/j.bmc.2004.07.013>.
  14. Czifrák K., Hadady Z., Docsa T., Gergely P., Schmidt J., et al. (2006) Synthesis of N-( $\beta$ -D-glucopyranosyl) monoamides of dicarboxylic acids as potential inhibitors of glycogen phosphorylase, *Carbohydr. Res.* 341, 947-956. <https://doi.org/10.1016/j.carres.2006.03.02>
  15. Poopeiko N.E., Kvasuyk E.I., Mikhailopulo I.A., Lidak M.J., (1985) Stereospecific Synthesis of  $\beta$ -D-Xylofuranosides of Adenine and Guanine, *Synthesis.* 6/7, 605-609. <https://doi.org/10.1055/s-1985-34318>.
  16. Sivets G.G, Sivets A.V., (2021) Synthesis of N-pentofuranosyl oxazolines and amides via selective transformations of acetonides of D-sugars, *Doklady of the National Academy of Sciences of Belarus*, ser. chem. Belarus ser. chem. 65, 3, 558-567. <https://doi.org/10.29235/1561-8323-2021-65-5-558-567>.
  17. Gosselin G., Puech F., Genu-Dellac C., Imbach J.-L., (1993) 1,2-Di-O-acetyl-5-O-benzoyl-3-deoxy-3-fluoro-D-xylofuranose. A versatile precursor for the synthesis of 3-deoxy-3-fluoro-D-xylofuranosyl nucleosides as antiviral agents, *Carbohydr. Res.* 249, 1-17. [https://doi.org/10.1016/0008-6215\(93\)84056-C](https://doi.org/10.1016/0008-6215(93)84056-C).
  18. Roy V., Zerrouki R., Krauz P.; Laumond G., Aubertin A.M., (2007) Synthesis and Antiviral Evaluation of Azt Analogues with A Spacer Arm, between Glucidic and Base Moieties. Part II, *Nucleosides, Nucleotides & Nucleic Acids.* 26, 413-421. <https://doi.org/10.1080/152577707011426153>.
  19. Chen S.-H., Lin S., King I., Spinka T., Dutschman G.E., et al. (1998) Synthesis and comparative evaluation of two antiviral agents:  $\beta$ -L-Fd4C and  $\beta$ -D-Fd4C, *Bioorg. Med. Chem. Lett.* 8, 3245-3250. [https://doi.org/10.1016/S0960-894X\(98\)00599-X](https://doi.org/10.1016/S0960-894X(98)00599-X).
  20. Soares F.F.P., Silva M.J., Doboszewski B., (2013) Deoxygenation at the C3 position of D- and L-arabinofuranose: stereospecific access to enantiomeric cordycepose derivatives, *Carbohydr. Res.* 380, 143-148. <https://doi.org/10.1016/j.carres.2013.07.017>.
  21. Genu-Dellac C., Gosselin G., Imbach J.-L., (1992) Preparation of new acylated derivatives of L-arabinofuranose and 2-deoxy-L-erythro-pentofuranose as precursors for the synthesis of L-pentofuranosyl nucleosides, *Carbohydr. Res.* 216, 249-255. [https://doi.org/10.1016/0008-6215\(92\)84166-P](https://doi.org/10.1016/0008-6215(92)84166-P).
  22. Lajsic S., Miljkovic D., Cetkovic G., (1992) An improved synthesis of D-amictose, *Carbohydr. Res.* 233, 261-264. [https://doi.org/10.1016/S0008-6215\(00\)84166-P](https://doi.org/10.1016/S0008-6215(00)84166-P).
  23. Haga M., Takano M., Tejima S., (1972) 3-O-Methyl-D-allose and a facile route to 2- and 3-O-methyl

- D-ribose, *Carbohydr. Res.* 21, 440-446. [https://doi.org.10.1016/S0008-6215\(00\)84925-3](https://doi.org.10.1016/S0008-6215(00)84925-3).
24. Whistler R. L., Doner L. W., (1970) D-Glucopyranosylation of cellulose acetate, *Carbohydr. Res.* 15, 391-395. [https://doi.org.10.1016/0008-6215\(00\)80455-3](https://doi.org.10.1016/0008-6215(00)80455-3).
25. Jiang D., He T., Ma L., Wang Z., (2014) Recent developments in Ritter reaction, *RSC Advances.* 4, 64936-64946. <https://doi.org.10.1039/c4ra10784e>.
26. Guerinot A., Reymond S., Cossy J., (2012) Ritter Reaction: Recent Catalytic Developments, *Eur. J. Org. Chem.* 1, 19-28. <https://doi.org.10.1002/ejoc.201101018>.
27. Klemer A., Kohla M.J., (1988) Eine Einfache Synthese von N-Acyl Glykosylaminen, *Carbohydr. Chem.* 7, 4, 785-797. <https://doi.org.1080/07328308808058945>.
28. Stalford S.A., Kilner C.A., Leach A.G., Turnbull W.B., (2009) Neighbouring group participation vs. addition to oxacarbenium ions: studies on the synthesis of mycobacterial oligosaccharides, *Org. Biomol. Chem.* 7, 23, 4842-4852. <https://doi.org.10.1039/b914417>.
29. Chao Ch.-Sh., Lin Ch.-Yu, Mulani S, Hung W.-Ch., Mong K.-K.T., (2011) Neighboring-Group Participation by C-2 Ether Functions in Glycosylations Directed by Nitrile Solvents, *Chem. Eur. J.* 17, 12193-12202. <https://doi.org.10.1002/chem.201100732>.
30. Schmidt R.R., Behrendt M., Toepfer A., (1990) Nitriles as Solvents in Glycosyl Reactions: Highly Selective  $\beta$ -Glycosid Synthesis, *Synlett.* 11, 694-696. <https://doi.org.10.1055/s-1990-21214>.
31. Braccini I., Derouet C., Esnault J., Herv'e du Penhoat C., Mallet J.-M., et al. (1993) Conformational analysis of nitrilium intermediates in glycosylation reactions, *Carbohydr. Res.* 246, 23-41. [https://doi.org.10.1016/0008-6215\(93\)84021-W](https://doi.org.10.1016/0008-6215(93)84021-W).
32. Kafle A., Liu j., Cui L., (2016) Controlling the stereoselectivity of glycosylation via solvent effects, *Can. J. Chem.* 94, 11, 894-901. <https://doi.org.10.1139/cjc-2016-0417>.
33. Hettikankanamalage A.A., Lassfolk R., Ekholm F. S., Leino R., Crich D., (2020) Mechanisms of Stereodirecting Participation and Ester Migration from Near and Far in Glycosylation and Related Reactions, *Chem. Rev.* 120, 7104-7151. <https://doi.org.10.1021/acs.chemrev.0c00243>
34. Soo K. K., Dae-Hwan S., (2011) Remote Participation of Protecting Groups at Remote Positions of Donors in Glycosylations, *Trends in Glycoscience and Glycotechnology.* 23, 53-66. doi.10.4052/tigg.23.53.
35. Wierenga W., Skulnick H.L., (1981) Stereochemical control as a function of protecting-group in 2-deoxy-d-erythro-d-pentofuranosyl nucleosides, *Carbohydr. Res.* 80, 41-52. <https://doi.org.10.1016/0008-6215/81/0000-0000/S>.
36. Kumar A., Kumar V., Dere R.T., Schmidt R.R., (2011) Glycoside Bond Formation via Acid-base Catalysis, *Org. Lett.* 13, 14, 3612-3615. <https://doi.org.10.1002/adsc.201100933>.
37. Nielsen M.M., Pedersen C.M., (2018) Catalytic Glycosylations in Oligosaccharide Synthesis, *Chem. Rev.* 118, 8285-8358. <https://doi.org.10.1021/ol201231v>.
38. Kumar A., Geng Y., Schmidt R.R., (2012) Silicon Fluorides for Acid-Base Catalysis in Glycosidations. *Adv. Synth. Catal.* 354, 1489-1499. <https://doi.org.10.1002/adsc.201100933>.
39. Smith J.R.L., Norman R.O.C., Stillings M. R., (1975) Synthesis of Oxazolines from Epoxides, *J. Chem. Soc. Perkin Trans I.* 13, 1200-1202. <https://doi.org.10.1039/P19750001200>.
40. Howell H.G., Brodfuehrer P.R., Brundidge S.P., Bengini D.A., Sapino C.Jr., (1988) Antiviral Nucleosides. A Stereospecific, Total Synthesis of 2'-Fluoro-2'-Deoxy- $\beta$ -D-arabinofuranosyl

Nucleosides, *J. Org. Chem.* 53, 85-88. <https://doi.org/10.1021/jo00236a017>.

41. McMillian M. K., Li L., Parker J.B., Patel L., Zhong Z., et al. (2002) An improved resazurin-based cytotoxicity assay for hepatic cells, *Cell. Biol. Toxicol.* 18, 157–173. <https://doi.org/10.1023/A.105559603643>.
42. Niles A.L., Moravec R.A., Riss T.L., (2008) Update on *in vitro* cytotoxicity assays for drug development, *Expert Opin. Drug Discov.* 3, 6, 655-669. <https://doi.org/10.1517/17460440802163960>.